IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:	
Stefan Pulst	**Confirmation No.:** 8912
Serial No.: 10/802,228	**Group Art Unit:** 1632
Filed: March 16, 2004	**Examiner:** Paul Dowell
For: METHODS AND COMPOSITIONS FOR THE TREATMENT OF OBESITY	

DECLARATION OF STEFAN PULST

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Stefan Pulst, hereby declare and state as follows:

1. I am the Director of the Division of Neurology at Cedars-Sinai Medical Center and hold the Carmen and Louis Warschaw Chair in Neurology. I am also Medical Director of the American Parkinson Disease Information and Referral Center and Co-Director of the Neuromuscular Center at Cedars-Sinai. In addition, I am Professor of Medicine and Neurobiology at the David Geffen School of Medicine at the University of California, Los Angeles. I am the Founding Chair of the Section on Neurogenetics of the American Academy of Neurology and the Scientific Director of the National Ataxia Foundation.

2. I hold a Medical Doctorate degree from the University of Hannover, Germany, and have received neurologic training in Germany and at Harvard Medical School. As an active researcher in neurology for more than 25 years, I have authored or co-authored more than 150 scientific papers and edited two neurology text books. My specific research areas are neurodegenerative disorders, in particular the dominant ataxias and Parkinson's disease, genes

involved in causing or preventing brain tumors and the role of these genes in development and neuronal functioning, muscle disease gene identification, as well as neuropsychiatry and genes involved in cognition. A copy of my current curriculum vitae is attached hereto as Exhibit A.

3. I have read the Office Action dated January 17, 2006 for Patent Application Serial No. 10/802,228 of which I am the named inventor. The '228 Application is directed to methods of treating obesity, comprising administering to a subject SCA-2 polynucleotides and SCA-2 polypeptides. I understand that the claims under examination have been rejected, *inter alia*, for lack of enablement. I also understand that the standard against which enablement is analyzed is whether a person of ordinary skill in the art could, by following a patent application's specification, practice the claimed invention with a reasonable expectation of success. It is my opinion that the claims at issue are enabled, for the reasons set forth below.

4. In the course of my research about the function of the Sca2 gene, I discovered that deficiency of ataxin-2, the product of the Sca2 gene, causes marked obesity in mice in the C57BL/6J/129X1/SvJ background. The degree of obesity is dosage dependent, i.e. knockout Sca2 (-/-) mice are more obese than +/- Sca2 heterozygotes, which in turn are obese compared to wild type (+/+) mice, indicating that decreased Sca2 levels are directly correlated with hyperphagia and body fat accumulation. In my opinion, it is highly unlikely that Sca2 deficient obesity is unique to the C57BL/6J/129X1/SvJ genetic and metabolic background of the mice used, as these hybrid mice capture sufficient genetic variability, given that the two parent strains (C57BL/6J and 129X1/SvJ) are genetically distinct. Seeing obesity in a genetically less homogeneous hybrid strain is also more akin to human genetic diversity and less likely to be due to epistatic interactions between a highly inbred strain and the respective mutation. Further, the C57BL/6J/129X1/SvJ strain is a good and predictable model for diseases, having been used in establishing mouse models for diseases such as obesity and diabetes. Finally, the obese phenotype observed in the Sca2 (-/-) mice is neither subtle (see Figure 2 of the patent application) nor truly metabolic, but rather brought about by a significant overconsumption of food, much like human obesity.

5. The Sca2 knockout and heterozygous mice will be used as a model for the treatment of obesity by delivering the Sca2 gene, ataxin-2 protein, and fragments thereof, to the

homozygotes, heterozygotes (and wild type as control), and measuring the feeding behavior and body weight of the different genotypes over several months to determine the amount of fat reduction and normalization in eating behavior in each.

6. First, the full length Sca2 gene will be delivered to homozygous, heterozygous and wild type mice. For this purpose, the Sca2 coding region will be inserted in a lentiviral vector and injected into the brains of two groups of obese Sca2 deficient mice, one group being the homozygous knockout (-/-), and the other the heterozygous (+/-) genotype. At the same time, a different set of knockout and heterozygous Sca2 deficient mice will receive injections with the Sca2 vector into muscle tissue.

7. Insertion of the coding region of Sca2 into a viral vector, such as a lentivirus, will either be performed by a skilled lab technician in my laboratory or outsourced to a vector facility, such as that of the Harvard Gene Therapy Initiative or the University of Pittsburgh Molecular Medicine Institute. The administration of the Sca2 vectors to the obese mice and controls will be performed by skilled laboratory technicians in my laboratory as a matter of routine. Measurement of food intake and body weight is also routinely performed in my laboratory. None of these tasks require undue experimentation or more than average skill in the art and I reasonably expect to see a measurable reduction in overeating and/or obesity in the mice treated.

8. The experiment will then be broadened to include other obese mouse models. This serves the dual purpose of determining the effect of Sca2 on other obese genotypes and elucidating the molecular mechanism of obesity and the interaction of Sca2 with other genes known to be involved in obesity. The obese mouse models ob/ob (leptin), db/db (leptin receptor), ay/a (obese yellow mouse), BDNF heterozygous, TrkB receptor mutants and serotonin receptor mutants will be used to assess the effect of Sca2 administration on body fat reduction and feeding behavior. Again, the performance of these experiments requires only routine skill and I reasonably expect to see some effect of Sca2 administration on one or more of these obese mouse models.

9. At a later point, the administration of less than full-length Sca2 fragments will be investigated for their effect on the obese mouse models mentioned herein. Because some of the functional domains of the ataxin-2 proteins are known, they will be used to define the fragments

that will be tested. We have previously identified domains in ataxin-2 (Figueroa et al., 2003; Huynh et al., 2003). These are an acidic domain comprising amino acids (aa) 280-458, Sm1 and Sm2 domains (aa 283-333), caspase domain (aa 396-399), a domain containing a clathrin-mediated trans-Golgi signal (aa 414-416), and ER-exit signal (aa 426-428) and a PABP interaction domain comprising aa 911-916. We will generate fragments containing these domains using PCR with primers corresponding to the respective DNA sequence, which incorporate extended sequences at their 5' ends to facilitate cloning into viral vectors using appropriate restriction enzymes.

10. The C57 strain is known to be prone to obesity owing to its preference for high fat food, whereas the 129 strains are known to be lean. Mutations in the C57 strain in the homozygous state, such as ob/ob and db/db, have been highly predictive of human obesity phenotypes. Because obesity occurs in Sca2-deficient mice with a mixed genetic background including that of the lean 129 strain, I reasonably expect the administration of human Sca2 gene and ataxin-2 protein and their fragments to be effective in certain types of obesity in humans. Significantly, obesity is even observed in heterozygous Sca2+/- mice, whereas other mouse mutants need to be homozygous to show an obesity phenotype. As outlined previously, the construction of Sca2 vectors is a matter of routine requiring no undue experimentation, as is the administration of the vectors and proteins and the determination of their effect on body fat reduction and eating behavior.

11. In addition, there are two lines of evidence implicating the SCA2 gene in human obesity phenotypes. First, several studies have found linkage to human chromosome 12q24, the genetic locus of the SCA2 gene. These include a linkage scan of dichotomous body mass index and obesity quantitative traits, which gave evidence for linkage on CHR 12q23-24 (Li et al, Diabetes 53: 812 (2004)). A genome wide linkage scan of obesity as a secondary effect of antipsychotic treatment also found evidence for linkage on 12q24 (Chagnon et al, Mol Psych 9:1067 (2004)). Secondly, my laboratory has conducted a study of 70 Caucasian children with a body mass index >30 and detected significant allelic association in the SCA2 gene. In my opinion, this evidence clearly corroborates our experimental data in the SCA2 deficient mouse model and points to the involvement of SCA2 in human obesity.

12. Thus, a person skilled in the art, when reading the description in the patent application, could, at the time the patent application was filed, easily administer the Sca2 gene and ataxin-2 protein, as well as fragments thereof, to treat obesity, without any experimentation going beyond routine experiments, and with a reasonable expectation of success.

13. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that willful false statements may jeopardize the validity of the application or any patent issuing thereon.

14. Executed this 13th day of June 2006, at Los Angeles, California.

Stefan M. Pulst

Enclosure: Exhibit A

CURRICULUM VITAE
STEFAN- M. PULST

PERSONAL HISTORY

Business address: Cedars-Sinai Medical Center
Division of Neurology (215 East)
Los Angeles, CA 90048
(310) 423-5166

Home address: 8125 Skyline Drive
Los Angeles, CA 90046
(323) 650-1349

Date of Birth: October 14, 1954

PROFESSIONAL EXPERIENCE

PRESENT POSITIONS:

Director and Carmen & Louis Warschaw Chair, Division of Neurology
Professor of Medicine and Neurobiology, University of California, Los Angeles

Scientific Director, Parkinson's Disease Research and Treatment Center
Medical Director, American Parkinson Disease Association Center
Director, Neurogenetics Laboratory
Co-Director, Neurofibromatosis & Neurogenetics Clinic
Co-Director, Neurogenetics Training Program

ACADEMIC APPOINTMENTS:

2001 – present	Professor of Neurobiology, University of California, Los Angeles
1997 - present	Professor of Medicine in Residence, University of California, Los Angeles
1992-1997	Associate Professor of Medicine in Residence, University of California, Los Angeles
1987-1992	Assistant Professor of Medicine in Residence, University of California, Los Angeles

Positions Held:

1986-Present	Research Scientist, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles
1988-1993	Clinical Coordinator, Division of Neurology, Cedars-Sinai Medical Center

1997-2002	Co-Director, MDA Neuromuscular Clinic, Cedars-Sinai Medical Center
1988-Present	Co-Director, Neurofibromatosis Clinic, Cedars-Sinai Medical Center
1990-Present	Director, Neurogenetics Laboratory, Cedars-Sinai Medical Center
1990-Present	Carmen and Louis Warschaw Chair of Neurology, Cedars-Sinai Medical Center
1993-Present	Director, Division of Neurology, Cedars-Sinai Medical Center
1994-Present	Scientific Director, Parkinson Disease and Alzheimer Disease Research and Treatment Centers, Cedars-Sinai Medical Center

EDUCATION:

1973-1977	Hannover Medical School, FR Germany
1977-1978	Harvard Medical School, Boston
1978-1979	Internship Hannover Medical School, FR Germany
1979	M.D. (Approbation zum Arzt)
1980	Medical thesis (Dr. med): Infrared Thermography, a new method for the study of lesions of the peripheral nervous system
1980-1981	Resident in Neurology, Hannover Medical School, FR Germany
1981-1982	Senior Resident, Longwood Area Neurological Program and Clinical Fellow in Neurology, Harvard Medical School, Boston
1982-1983	Chief Resident, Longwood Area Neurological Program and Clinical Fellow in Neurology, Harvard Medical School, Boston
1983-1984	Visiting Research Neurologist, Brain Tumor Research Center, University of California, San Francisco
1984-1986	Postdoctoral Fellow, Department of Physiology, Division of Neurobiology, University of California, San Francisco

MEDICAL LICENSURE: California # A42196

BOARD CERTIFICATION: American Board of Psychiatry and Neurology

PROFESSIONAL ACTIVITIES:

Committee Service-National:

1993-1997	Meeting Subcommittee of the Educational Committee, American Academy of Neurology, Member
1993-1999	National Ataxia Foundation Scientific Advisory Board, Member.
1999-2006	National Ataxia Foundation Scientific Advisory Board, Chair.
2000	NIH Mammalian Genetics Study section, ad hoc reviewer.
2000- present	FARA/NIH Friedreich ataxia clinical trial steering committee, member.
2000- 2003	American Academy of Neurology, Committee on Sections (COS), member.
2000-2003	American Academy of Neurology, Annual Meeting, Scientific Program Subcommittee, member.
2001	US Secretary of Health Roundtable on Genetic Education, member.
1999- 2002	American Academy of Neurology, Section on Neurogenetics, Founding Chair
1998- present	Cooperative Ataxia Group, Founding Member.
1999- present	Machado-Joseph disease Foundation Scientific Advisory Board, Member.
1999- 2006	National Ataxia Foundation, Scientific Director.
2002- present	American Academy of Neurology, Section on Neurogenetics, Executive Committee
2003-2008	American Academy of Neurology, Science committee, member
2004-2007	Genes, Health and Disease (formerly Mammalian Genetics) Study section, NIH, permanent member
2005-2006	American Academy of Neurology, Basic Science Subcommittee, Chair.
2006-present	National Ataxia Foundation Executive Board, Member.
2006-present	American Academy of Neurology, Presidential Nominating Committee, member.
2006-present	American Academy of Neurology, Science Committee, Chair.

Committee Service- UCLA School of Medicine

1995-1999	Department of Medicine, Committee for Appointments and Promotions, member.
2000-2004	Department of Neurobiology, Committee for Appointments and Promotions, member.

Committee-Service- Cedars-Sinai Medical Center:

1993- present	Performance Improvement Committee, Department of Medicine, Cedars-Sinai Medical Center, member.
1996- 2001	Stroke, Continuous Value Improvement Project. Team Leader
1991-1995	Committee for Reappointments, Appointments, Promotions, Policies and Procedures, Division of Neurology, Cedars-Sinai Medical Center, Member.
2000	Institutional Review Board, member.
2001	Integrated Medicine Performance Improvement Committee, Chair
2004-2005	Chair, search committee for Director Neuromuscular services
2004-2005	Business planning group for a Memory Disorders Center
2004-2005	Chair, search committee for Associate Director Neurophysiology Laboratory
2004-2005	Chair, business planning group for a MEG center
2004-2005	Chair, business planning group for an ALSA-sponsored ALS center
2005	Chair, search committee for Director Movement Disorders Program
2005	Chair, business planning group for a Movement disorder Center
2006	Chair, Neuroscience Center Strategic Planning Task force, Centers of Excellence and Educational Programs

Membership in Professional Organizations

American Association for the Advancement of Science
American Academy of Neurology
American Association for Cancer Research
American Society of Human Genetics
American Society of Neurophysiological Monitoring
World Federation of Neurology (Neurogenetics)
National Ataxia Foundation

PROFESSIONAL ACTIVITIES (continued):

Editor-in-Chief

Current Genomics (Co-editor-in-chief with C. Neri 2001-2003)	2000 - 2003

Editorial Boards

Nature Clinical Practice Neurology	Editorial Board	2005 - present
Neurogenetics	Editorial Board	2004 - present
Continuum (AAN CME series)	Editorial Board	2003 - present
Experimental Neurology	Editorial Board	2003 - present
Journal of Cerebellum	Editorial Board	2000 - present
NeuroMolecular Medicine	Editorial Board	2001 - present
Journal of Molecular Neuroscience	Editorial Board	1999 - present
Encyclopedia of Neurology	Associate Editor	1999 - 2003
Lancet Neurology Network Commentary	Associate Editor	1998 - 2002

Reviewer: Journals (ad hoc)

Nature Genetics
New England Journal of Medicine
American Journal of Human Genetics
Human Genetics
Human Mutation
Encyclopedia of Molecular Biology and Molecular Medicine
Movement disorders
Brain
Human Molecular Genetics
Neurology
Genes, Chromosomes and Cancer
American Journal of Medical Genetics
Annals of Neurology
Neurobiology of Disease
Journal of Experimental Pathology

PROFESSIONAL ACTIVITIES (continued):

Reviewer: Grants

National Institutes of Health, Genes, Health and Disease study section, member, 2005-present
National Institutes of Health, Mammalian Genetics study section, member, 2004-2005
National Ataxia Foundation, Scientific review committee, Chair 1999-present
National Institutes of Health, Special Emphasis Panel, Mammalian Genetics, Chair, 2001.
National Neuroscience Institute, Singapore, reviewer, 2002
National Institutes of Health, Neurology C & Mammalian Genetics, reviewer (ad hoc), 2000
University Grants committee, Research Grants Counsel, Hong Kong, China, reviewer 1999
American Cancer Society, reviewer, 1998
American Institute for Biological Sciences (Review committee for the Neurofibromatosis Research Program of the Department of Defense), reviewer (ad hoc), 1997
Veterans Administration (ad hoc),
American Alzheimer Disease Association (ad hoc),
American Health Assistance Foundation (ad hoc).

Reviewer: Meeting Abstracts

American Academy of Neurology, abstract reviewer 1993- 2003
American Academy of Neurology, Chair, neurogenetics abstract review 2001- 2003

CHAIRPERSON SCIENTIFIC SESSIONS

Co-chair, session on Pediatric Genetics, American Academy of Neurology, San Diego 1992.
Co-chair, session on Neurogenetics and Genetic Linkage Analysis, American Academy of Neurology, New York, 1993.
Co-chair, session on Cancer Genetics, American Society of Human Genetics, New Orleans, 1993.
Co-chair, session on Neurogenetics, American Academy of Neurology, Seattle, 1995.
Co-chair, Neuromuscular Genetics, American Academy of Neurology, San Francisco, 1996.
Co-chair, session on "Neurofibromatosis 2". 4th Annual Meeting of the von Recklinghausen Society, Hamburg, Germany, 1996.
Co-Chair, session 'Neurogenetics III'. American Academy of Neurology, Boston, 1997
Chair: session on disease genes. 4th International Chromosome 12 Workshop. Nice 1997.
Co-chair: session on genetic aspects. 4th International Workshop on Machado-Joseph Disease. Curitiba, Brazil, 1997.
Co-Chair, "Neurogenetics II", 50th meeting of the American Academy of Neurology, Minneapolis, MN, 1998.

CHAIRPERSON SCIENTIFIC SESSIONS (continued)

Co-Chair, "Neurogenetics III", 51st meeting of the American Academy of Neurology, Toronto, Canada, 1999.
Co-Chair, "Neurofibromatosis 1, structure and function". European NF Meeting, Ulm, Germany, 1999.
Co-chair, "The inherited ataxias". Satellite meeting, Movement disorder Society, Seattle, 1999.

Chair, International Symposium of the Japanese Genome Project. Elucidation of molecular mechanisms of human brain disease based on genome analysis. Session 4: Animal models. Niigata, Japan, 1999.

Topic Chair, Neurogenetics, Meeting of the American Academy of Neurology, 2001.

Topic Chair, Neurogenetics, Meeting of the American Academy of Neurology, 2002.

Topic Chair, Neurogenetics, Meeting of the American Academy of Neurology, 2002.

Topic Chair, Neurogenetics, Meeting of the American Academy of Neurology, 2003.

Chair, Enhanced Vertical Integration Neurogenetics, Meeting of the American Academy of Neurology, San Francisco, 2004.

Co-chair, Mechanisms of Ataxia, NAF investigator meeting, Tampa, Fl 2005.

Co-chair and co-organizer (with Drs. R. Roos & B. Banwell): Frontiers in Clinical Neuroscience Plenary Session: stem Cells in Neurology. American Academy of Neurology, San Diego, 2006.

HONORS AND SPECIAL AWARDS

1975	Cross Country State Championships (Lower Saxony), 3rd place, team competition.
1975	Cross Country State Championships (Lower Saxony), 2nd place, team competition.
1975	German National Cross Country Championships, 6th place, Team Competition, Berlin, FR Germany.
1974-1979	Studienstiftung des Deutschen Volkes (German National Merit Scholarship)
1977-1978	Foreign Studies Scholarship, Studienstiftung des Deutschen Volkes, for studies at Harvard Medical School
1983-1984	Foreign Training Grant, Deutsche Krebshilfe (German Cancer Society)
1986	NIH Neuroscience Training Grant
1991	Carmen and Louis Warschaw Endowed Chair for Neurology
1996	American Society of Human Genetics, mentor for Alex Nechiporuk, winner for best presentation, pre-doctoral clinical.
1999	Neurofibromatosis, Inc. Scholar Award.
1999	Scientific Director, National Ataxia Foundation
1999	Founding Chair, Section on Neurogenetics, American Academy of Neurology
2000	Keynote Speaker. First Annual Mayo Research Forum. "From Molecules to Mankind". Rochester, MN, 1999

HONORS AND SPECIAL AWARDS (continued)

2001	Presidential Lecture, Society for Biological Psychiatry, Chicago.
2000	Keynote Speaker, Vietnamese Society of Clinical Biochemistry, Hanoi Vietnam.
2002	Editor-in-Chief, Current Genomics.
2003	Science Committee, American Academy of Neurology
2005	Chair, Plenary Session 'Frontiers in Clinical Neuroscience', American Academy of Neurology, Miami Beach, 2005
2006	Co-chair; Frontiers in Clinical Neuroscience Plenary Session, American Academy of Neurology, San Diego, 2006
2006	Chair, Science Committee, American Academy of Neurology

COMMUNITY SERVICE

1994	American Youth Soccer Organization, Coach Boys Division 5
1995	American Youth Soccer Organization, Coach Girls Division 5
1996	American Youth Soccer Organization, Coach Boys Division 4
1997	American Youth Soccer Organization, Assistant Coach Boys Division 3
1998	American Youth Soccer Organization, Coach Boys Division 3

GRANTS:

1987-1988	NIH Biomedical Research Support Grant: Isolation of expressed sequences from the human genome. $10,000; 1/1/87 - 6/30/87. Principal Investigator
1987-1991	Walker Foundation: Molecular analysis of Neurofibromatosis 1. $200,000; 1/1/87 - 2/31/91. Principal Investigator
1988-1990	Young Investigator Award, National Neurofibromatosis Foundation: Neurofibromatosis: a novel molecular approach to the detection of deletions and an analysis of variant forms. $50,000; 12/1/88 - 11/30/90. Principal Investigator
1989-1991	American Health Assistance Foundation: Identification of the Familial Alzheimer Locus: A Fine Structure Physical Map of Chromosome 21. $195,000.; 4/1/89 - 3/31/91. Co-Principal Investigator (with J. R. Korenberg)
1991-1992	American Health Assistance Foundation: Identification of the Familial Alzheimer Locus: A fine structure physical map and linkage analysis of the chromosome 21 pericentromeric region. $100,000, 4/1/91 - 3/31/92. Co-Principal Investigator (with J. R. Korenberg)
1992-1993	House Ear Institute Foundation. Clinical and molecular analysis of Neurofibromatosis Type 2. Program Project grant $157,000; 8/1/92 - 7/31/93. Co-Principal Investigator (with B. Shannon)
1992-1994	American Health Assistance Foundation: Familial Alzheimer disease and the 21 centromere. $188,000; 4/1/92 - 3/31/94. Co-Principal investigator (with J. R. Korenberg)
1991-1994	Walker Foundation: Anatomical and biochemical studies of the NF1 gene product. $130,000; 7/1/91 - 6/30/94. Principal Investigator
1990-1995	National Institutes of Health: Neurofibromatosis: a molecular genetic approach. NINDS Clinical Investigator Development Award. $ 404,374; 9/1/90 - 8/31/95. Principal Investigator
1993-1995	American Cancer Society. Mutations in the NF2 gene. $ 180,000 12/1/93 - 11/30/95. Principal Investigator
1994-1997	Walker Foundation: Function of neurofibromin during neuronal differentiation. $120,000; 7/1/94 - 6/30/97. Principal Investigator
1995-1996	Janssen Pharmaceuticals. Phase 3 trial of Lubeluzole in patients with acute stroke. $99,000. Principal Investigator
1996-2000	National Institutes of Health (RO1 NS33123): Spinocerebellar ataxia type 2: gene and gene product. 2/1/96-1/31/2000. $889,000. Principal Investigator
1997-1998	Genentech. Phase 3 trial of Activase in the treatment of acute stroke. $100,000. Principal Investigator.
1997-1999	National Institutes of Health: NF2 binding proteins. 7/1/97 - 6/30/99. $70,000 (Mentor for Daniel Scoles, Ph.D.)

GRANTS (continued):

1998-2001	National Institutes of Health: Novel muscular dystrophy linked to keloids, 7/1/98 - 6/30/2001 $325,078, Mentor for Cameron Adams, M.D.
1999-2001	Joseph Drown Foundation: The genetics of Parkinson's disease. 2/1/99 - 1/31/01 $170,000 (Principal investigator).
1998-2001	National Institutes of Health (RO1 NS37883): Characterization of NF2 binding proteins. 11/1/98-10/31/2002. $561,594 (Principal Investigator).
1999-2002	Department of Defense (DAMD 17-99-1-9548) NF2 in Hrs-mediated signal transduction. 10/1/99-9/30/2002. $683,090. (Principal Investigator).
1999-2000	NIH equipment Grant NF2 Binding Proteins. $75,000 (Principal Investigator).
1998-2002	National Institutes of Health (RO1 NS37883): Characterization of NF2 binding proteins. 11/1/98-10/31/2001. $561,594 (Principal Investigator).
2000-2001	National Institutes of Health (1NS033123-05S1): Spinocerebellar ataxia type 2: gene and gene product. Imaging supplement. $50,000.
2000-2003	Department of Defense (DAMD) Expression profiling of cell lines expressing regulated NF2 transcripts. 7/1/2001 - 6/30/2003. $ 301,385 (Principal Investigator).
2000-2004	FRIENDS of Neurology: The genetics of Attention Deficit Disorder. 2/1/99 - 1/31/2001, $53,000 (Principal investigator).
2000-2006	National Institutes of Health (RO1 NS33123): Spinocerebellar ataxia type 2: gene and gene product. 3/1/00-2/28/2006. $1,289,000 (Principal Investigator).
2003	National Ataxia Foundation. Identification of modifying alleles in the spinocerebellar ataxia type 2 (SCA2) population in Cuba. 01/01/03-12/31/03. $35,000 (Principal Investigator).
2004-2005	National Institutes of Health (1NS033123-05S1): Spinocerebellar ataxia type 2: gene and gene product. Supplement: Identification of a novel Filipino ataxia. $35,000.
2004-2005	Altropane SPECT in patients with tremor; site neurologist (Co-investigator), Boston Life Sciences
2003- 2006	National Institutes of Health (1R01 HG003228): Use of Genetics in Neurologists' Clinical Practices (Site-PI); Project PI: C. Browner
2005	National Ataxia Foundation. Identification of a novel ataxia in Filipinos. 01/01/05-12/31/05. $10,000 (Principal Investigator).

GRANTS (continued):

2005-2008	Department of Defense (DAMD) Animal models of NF2. 7/1/2005 - 6/30/2008. $ 1,000,035 (Principal Investigator).
2005-2010	National Institutes of Health KO1

Parkin binding Proteins
07/01/05-6/30/07. $750,000 (Mentor for Dr. D. Huynh)

2005-2007 American Academy of Neurology Ray Adams Clinical research Award
Novel Ataxia in Filipinos.
07/01/05-6/30/07. $140,000 (Mentor for Dr. Michael Waters)

2005-2006 Drown Foundation
Parkin and protection against paraquat and rotenone in vitro.
7/01/2005-6/30/06, $ 40,000.

2005-2007 National Institutes of Health R21
Novel treatments for ataxia.
07/01/05-6/30/07. $395,000 (Co-Principal Investigator with Dr. Heike Wulf)
CSMC subcontract $195,001

2005-2007 National Institutes of Health R21
Parkin binding proteins.
07/01/05-6/30/07. $395,000 (Principal Investigator).

2006 National Ataxia Foundation. Mutation analysis of KCNC3 in sporadic and familial ataxias.
01/01/05-12/31/05. $39,000 (Principal Investigator).

2006-2011 National Institutes of Health Udall Parkinson disease Center (Center-PI. M.F. Chesselet)
Parkin binding proteins. 5-1-06 to 4-30-11
$1,105,222 (Principal Investigator Project 4)

PATENTS

Title: Nucleic Acids Encoding Ataxin-2 Binding Proteins
Inventors: **Stefan M. Pulst**; Hiroki Shibata
Patent No.: 6,194,171
Issue Date: February 27, 2001

Title: Nucleic Acid Encoding Schwannomin-Binding-Proteins and Products Related Thereto.
Inventors: **Stefan M. Pulst**; Daniel R. Scoles
Patent No.: 6,376,174
Issue Date: April 23, 2002

Title: Transgenic Mouse Expressing a Polynucleotide Encoding a Human Ataxin-2 Polypeptide.
Inventors: **Stefan M. Pulst**; Duong P. Huynh
Patent No.: 6,515,197
Issue Date: February 4, 2003

Title: Ataxin-2 Binding Proteins
Inventors: **Stefan M. Pulst**; Hiroki Shibata
Patent No.: 6,617,430
Issue Date: September 9, 2003

Title: Methods of Detecting Spinocerebellar Ataxia-2 Nucleic Acids
Inventor: **Stefan M. Pulst**
Patent No.: 6,673,535
Issue Date: January 6, 2004

Title: Nucleic Acid Encoding Spinocerebellar Ataxia-2 and Products Related Thereto
Inventor: **Stefan M. Pulst**
Patent No.: 6,844,431
Issue Date: January 18, 2005

Title: Schwannomin-Binding-Proteins.
Inventors: **Stefan M. Pulst**; Daniel R. Scoles
Patent No.: 6,960,650
Issue Date: Nov 1, 2005

INVITED LECTURES - LOCAL

1. Lesions of the peripheral sympathetic nervous system. Meeting of the Southwest German Neurological Society 1980, Baden-Baden, West Germany.
2. Thermography in the diagnosis of peripheral nerve lesions. Meeting of the German Thermographic Society, 1980, Freudenstadt, West Germany.
3. Genetic linkage analysis of Familial Alzheimer Disease. UCLA Symposium on Alzheimer Disease, 1989, Los Angeles.
4. Molecular Neurogenetics. 18th Annual Neurology Symposium, Kaiser Foundation Hospitals, 1991, Los Angeles.
5. Ocular findings in NF1 and NF2. Conference on 'Genetic disease and the Eye', 1992, Los Angeles.
6. Molecular Biology of Meningiomas. UCLA symposium on clinical neurosurgery, 1992, Los Angeles.
7. The Neurofibromatoses. Neurology Grand Rounds, Sepulveda Veterans Administration Medical Center, 1992, Los Angeles.
8. Neurofibromatosis: clinical and molecular aspects. Conference on 'Genetic disease and the eye', 1993, Los Angeles.
9. Molecular Neurogenetics. Kaiser Permanente Pediatric Symposium, 1993, San Diego.
10. Neurogenetics. The Martin Haet Lectureship at CSMC, Los Angeles, 1994.
11. Neurogenetics: Back to the Future. Medical Symposium of the Graduate Internist Society, Los Angeles, 1994.
12. The Neurofibromatoses. UCLA Molecular Biology Institute Lecture Series, Los Angeles, 1995.
13. Neurofibromatosis type 1 and 2 - clinical and molecular genetic studies. Third conference on genetic disease and the eye. Cedars-Sinai Medical Center, Los Angeles 1996.
14. Recent advances in Neurogenetics. Psychiatry Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, 1996.
15. Molecular genetic testing for neurologists and neurosurgeons. Los Angeles Neurological Society, Los Angeles, 1997.
16. Recent advances in neurogenetics. UCLA Intercampus Genetics Training Program. Los Angeles, 1997.
17. The inherited ataxias. Neurology Grand Rounds, UCLA School of Medicine, Los Angeles 1997.
18. Identification of novel ataxia genes. Neurology Grand Rounds, USC School of Medicine, Los Angeles, 1997.
19. Health and Management Issues in Neurofibromatosis, National Neurofibromatosis Foundation California Chapter, San Diego, California, 1998.

INVITED LECTURES – LOCAL (continued)

20. Unstable DNA Repeats, Research Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA 1998.

21. Lecture on Neurofibromatosis, Cranial Facial Group Noon Conference, Cedars-Sinai Medical Center, 1998.
22. SCA2: a prototypic polyQ disease ?. Research Grand Rounds, Harbor-UCLA, 1999.
23. Polyglutamine diseases, paradigms for protein misfolding: the case of SCA2. Medicine Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, 1999.
24. The inherited ataxias. Neurology Grand Rounds, West Los Angeles Veteran's Administration Medical Center,1999.
25. Polyglutamine diseases, the model of SCA2. UCLA Department of Neurobiology, Los Angeles, 2001.
26. Update on SCA2: UCLA Ataxia club. Los Angeles 2002.
27. Fidel's ataxia: from a rare mendelian disease to a public health problem in Cuba. Cedars-Sinai Medical Center, Los Angeles, 2002.
28. Molecular Testing in Neurology. Neurology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, 2004.
29. Spinocerebellar Ataxia type 2: Of mice and men (and worms, too), UCLA, ACCESS Neurogenetics affinity group, Los Angeles, 2004.
30. Obesity in the SCA2 Knockout mouse. UCLA, Endocrinology Grand Rounds, Los Angeles, 2004.
31. Spinocerebellar Ataxias. Psychiatry Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, 2005.

INVITED LECTURES - NATIONAL

1. Clinico-pathological conference: Deterioration in a patient with a brain tumor. Neurology Grand Rounds, Brigham and Women's Hospital 1983, Boston.
2. The bag cell neurons of Aplysia California as a peptidergic multi-transmitter system. Harvard Medical School, 1986, Boston.
3. Fine-mapping of the Alzheimer amyloid plaque protein precursor on chromosome 21. University of Alabama, 1988, Birmingham.
4. Alzheimer disease and Down Syndrome: Molecular studies on Chromosome 21. State University of New York, 1988, Buffalo.
5. Alzheimer disease and Down syndrome: Fine-structure map of Chromosome 21. Medical College of Pennsylvania, 1988, Philadelphia.
6. Methods in molecular genetics. American Academy of Neurology, Washington, D.C. 1994.
7. Role of the genes for NF1 and NF2 in cancer and development. Plenary Session, National Meeting of the March of Dimes Foundation, Orlando, Florida, 1994.
8. Methods and Strategies in Molecular Genetics. 47th Annual Meeting of the American Academy of Neurology, Seattle, Washington, 1995.
9. Molecular genetic Testing. 47th Annual Meeting of the American Academy of Neurology, Seattle Washington, 1995.
10. The Phakomatoses, Pediatric Grand Rounds, UC Irvine, 1996.
11. Methods and Strategies in Molecular Genetics. 48th Annual Meeting of the American Academy of Neurology, San Francisco,1996.
12. Molecular genetic Testing. 48th Annual Meeting of the American Academy of Neurology, San Francisco, 1996.
13. The NF2 tumor suppressor, Neurology Grand Rounds, Brigham and Women's Hospital, Harvard Medical School, Boston, 1996
14. The dominant hereditary ataxias: identification of the gene for spinocerebellar ataxia type 2 (SCA2). Meeting of the National Ataxia Foundation, Jackson, Mississippi, 1997
15. Neurofibromatosis 2: Phenotype, mutations, and function. University of Mississippi, Jackson, Mississippi, 1997
16. Positional cloning of the gene for spinocerebellar ataxia type 2 (SCA2). University of Utah, Salt Lake City, Utah, 1997
17. Methods and Strategies in Molecular Genetics. 49th Annual Meeting of the American Academy of Neurology, Boston, 1997.
18. Molecular genetic Testing. 49th Annual Meeting of the American Academy of Neurology, Boston, 1997.
19. Functions of schwannomin. NIH/HEI/NNFF meeting on future directions in NF2 research. Bethesda, Maryland, 1997.

INVITED LECTURES - NATIONAL (continued)

20. Identification of the gene for spinocerebellar ataxia type 2. Neurology Grand Rounds, Georgetown University, Washington, DC, 1997.
21. The autosomal dominant ataxias. Neurology Grand Rounds, UCSD School of Medicine, San Diego, 1997.
22. Treatment strategies for autosomal dominant ataxias. National Institutes of Health. Bethesda, 1998.
23. Spinocerebellar ataxia type 2, Neurology Grand Rounds, University of Washington, Seattle, 1998.
24. The spinocerebellar ataxias. Neurology Grand Rounds, Department of Neurology, Medical University of South Carolina. 1999.
25. Advances in the spinocerebellar ataxias. Neurology Grand Rounds, Department of Neurology, Vanderbilt University, Nashville, Tennessee. 1999.
26. The Neurofibromatoses. 'State-of-the-art lecture', Meeting of the Western Society of Medicine, Carmel, Ca, 1999.
27. Molecular-genetic testing for inherited ataxias. American Academy of Neurology, Toronto, Canada. 1999.
28. The inherited ataxias. Neurology Grand Rounds, Emory University. Atlanta, Georgia, 1999.
29. The autosomal dominant spinocerebellar ataxias. Neurology Grand Rounds, Southwestern University, Texas, 1999.
30. SCA2 and SCA10, an update. Joint Meeting of the National Ataxia Foundation Association with the Annual Meeting of the American Neurological Association, Seattle, 1999.
31. The autosomal dominant spinocerebellar ataxias. Georgia Neurological Society, Atlanta, Georgia, 1999.
32. Spinocerebellar Ataxia Type 2: From gene isolation to animal models. University of Florida, Gainesville, 2000.
33. Progress in ataxia research. Partners Neurology Program MJD conference, Harvard Medical School, Fall River, Massachusetts, 2000.
34. Neurogenetics. Course 'Neurology Update'. American Academy of Neurology, San Diego, California, 2000.
35. The expanding world of the ataxias. Presidential lecture, Society of Biological Psychiatry. Chicago, 2000.
36. The dominant ataxias. Neurology Grand Rounds. University of New Jersey Medical School, Newark, 2000.
37. The hereditary ataxias: will the lumpers carry the day ? Neurology Grand Rounds, Hahnemann Medical School, Philadelphia, 2000.
38. The inherited spinocerebellar ataxias: from arrays to mouse models. Neurology Grand rounds, Stanford University, Palo Alto, 2000.

INVITED LECTURES - NATIONAL (continued)

39. The dominant ataxias. Brain Awareness Symposium, Saint Louis University, Saint Louis, 2001.
40. Clinical Frontiers: Genetics and pathophysiology of the ataxias. Mystic Lake, MN, 2001
41. Spinocerebellar ataxia type 2: human phenotypes, mouse models, and normal gene function. "From genes to motor control." University of Minnesota, Minneapolis, 2001.

42. Spinocerebellar ataxia type 2 (SCA-2). The hereditary ataxias. A symposium of the Society of Experimental Neuropathology under the auspices of the American Neurological Association, Chicago, 2001.
43. The dominant cerebellar ataxias. Neurology Grand Rounds. University of Texas, Dallas, 2001.
44. The inherited cerebellar ataxias. Neurology Grand Rounds, University of Indiana, Indianapolis, Indiana, 2001.
45. The inherited ataxias. Neurology Grand Rounds, University of Nevada Medical School, Las Vegas, 2001.
46. Inherited Ataxias. Neurology Grand Rounds, University of Rochester, Rochester, New York, 2002.
47. Inherited Ataxias and Genetic Testing. Neurology Grand Rounds, UC San Diego, 2002.
48. The recessive and dominant ataxias. Neurology Grand Rounds, Saint Louis, 2002.
49. Spinocerebellar ataxia type 2: In vitro studies and modifying genes. Emory University, Atlanta, 2003
50. Fidel's ataxia: from a rare mendelian disease to a public health problem in Cuba. Neurology Grand Rounds, Harvard Medical School, Boston, 2003.
51. The dominant cerebellar ataxias. Neurology Grand Rounds, Beth Israel Hospital, New York, 2003.
52. The inherited ataxias. Neurology Grand Rounds, George Washington University, Washington, D.C., 2004.
53. Spinocerebellar Ataxia type 2: Of mice and men (and worms), Michigan Children's Hospital , Wayne State University, Detroit, 2004.
54. The dominant ataxias. Neurology Grand Rounds, University of Kentucky, Lexington, 2004.
55. The inherited ataxias. Neurology Grand Rounds, Dartmouth Medical School, Hanover, N.H., 2004.
56. Spinocerebellar Ataxia 2: From neurodegeneration to obesity. Seminar, Department of Genetics, Baylor College of Medicine, Houston, TX, 2005.
57. Ion channels and degenerative ataxias: Department of Pharmacology, UC Davis School of Medicine, Davis, CA, 2005.
58. Potassium channel mutations in degenerative ataxias: Department of Physiology, University of Texas, Dallas, TX. 2005.

INVITED LECTURES - NATIONAL (continued)

59. Genetics Of the Ataxias: Meeting of the American academy of Neurology, San Diego, 2006.
60. The inherited ataxias. San Diego Neurological Society, San Diego 2006.
61. Dominant Ataxias and Ion Channels. Neurology Grand Rounds, University of California San Diego, 2006.

INVITED LECTURES – INTERNATIONAL

1. Paraneoplastic brainstem encephalitis. Pula Neurological Meeting, 1981, Pula, Yugoslavia.
2. Current concepts in brain tumor therapy. Hannover Medical School 1984, Hannover, West Germany.
3. Functional implications of co-existing peptide neurotransmitter in the marine mollusk Aplysia. University of British Columbia, 1986, Vancouver.
4. PFGE analysis of patients with neurofibromatosis and achondroplasia. 2nd International NF gene linkage conference, 1988, New York City.
5. The achondroplasia gene is not linked to the NF region on Chromosome 17. International Consortium for Gene Cloning, 1989, New York City.
6. Chromosome 21 physical map: order of DNA probes linked to Familial Alzheimer Disease. International Symposium on Trisomy 21. 1989, Rome.
7. Prenatal molecular diagnosis of the neurofibromatoses. International Neurofibromatosis Symposium, 1990, Hamburg.
8. Linkage analysis of Familial Spinal Neurofibromatosis. International Consortium for Gene Cloning, 1990, New York City.
9. Expression of the NF1 gene product in human neuroblastoma and rat CNS. The NNFF international consortium on gene cloning and gene function of NF1 and NF2. 1992, Salt Lake City.
10. Genetic linkage analysis of a pedigree with familial meningiomas and ependymomas. The NNFF International Consortium on Gene Cloning and Gene Function of NF1 and NF2. 1992, Salt Lake City.
11. Variant neurofibromatosis. International NF meeting, Hamburg, Germany, 1993.
12. Cloning and mutation analysis of the NF2 gene. 3rd Annual Meeting of the Von Recklinghausen Society, Hamburg, Germany, 1993.
12. Genetic map of the SCA2 region on human chromosome 12. International Workshop on human chromosome 12. Yale University, New Haven, 1994.
14. Neurofibromatosis 2. Plenary Symposium "Nucleic Acids and the Molecular Basis of Disease"., Gesellschaft fur Biologische Chemie (German Biochemical Society), Hannover, Germany, 1995.
15. Neurofibromatosis type 2: Phenotype, gene mutations and schwannomin function. Satellite Symposium 'Molecular biological aspects of neuromuscular diseases'. Hannover, Germany, 1995.
16. Physical map of the SCA2 region. Third International Chromosome 12 Workshop. University of Leuven, Leuven, Belgium, 1995.
17. What is new with SCA2 and NF2. Heinrich-Heine Universitaet, Duesseldorf, Germany 1996.
18. Positional cloning of a new gene for inherited ataxia. Philips Universität, Marburg, Germany 1996.

INVITED LECTURES - INTERNATIONAL (continued)

19. Molecular and clinical studies of NF2 mutations. 4th Annual Meeting of the von Recklinghausen Society, Hamburg, Germany, 1996.
20. Physical map of 12q24.1. 4th International Chromosome 12 Workshop. Nice 1997.
21. The Biology of SCA2. Session on disease genes, 4th International Chromosome 12 Workshop. Nice 1997.
22. The gene for spinocerebellar ataxia type 2 (SCA2). International ataxia meeting, Montreal, Canada, 1997
23. Spinocerebellar ataxia type 2. 4th International Workshop on Machado-Joseph Disease, Curitiba, Brazil, 1997
24. Schwannomin binding proteins. International Consortium for NF1 and NF2 Function. Aspen, Colorado, 1998.
25. Spinocerebellar Ataxia type 2. International Congress of Genetics. Beijing, China, 1998.
26. Spinocerebellar ataxia 2. International Conference on "Cerebellar functions and genetics in health and disease". Tübingen, Germany, 1998.
27. NNFF International Consortium for Molecular biology of NF1 and NF2, Boston, 1999.
28. SCA2 and NF2: From neuronal death to Schwann cell proliferation. Decode Genetics, Reykjavik, Iceland, 1999.
29. Neurofibromatosis 2. 8th European Neurofibromatosis Meeting. Ulm, Germany, 1999.
30. An up-date on SCA2 and SCA10. International Symposium on "Elucidation of molecular mechanisms of human brain disease based on genome analysis". Niigata, Japan, 1999.
31. Polyglutamine disorders. Biotechnologia '99, La Habana, Cuba, 1999.
32. The dominant ataxias: Models for the understanding of neurogenetic disorders. Keynote address at the meeting of the Vietnamese Society for Clinical biochemistry. Hanoi, Vietnam, 2000.
33. Spinocerebellar ataxia type 2: From patients to mouse models and microchips. Hong Kong University, Hong Kong, 2001.
34. Spinocerebellar ataxia type 2: in vitro and in vivo models. University of Hamburg, Germany, 2002.
35. European Ataxia conference, Key note lecture: Ataxia disease models, Spoleto, Italy, 2002.
36. Gordon Conference on CAG diseases, key note speaker, session on ataxias: SCA2: from in vitro models to modifying alleles. Il Ciocco, Italy, 2003.
37. International Movement disorder Society Meeting, Ataxia course, Rome, 2004.
38. Von Recklinghausen Gesellschaft Arbeitstagung, NF2-binding proteins, Hamburg, Germany 2004.
39. ARSACS Conference, SCA2: models and modifiers, Montreal, Canada, 2004

SYMPOSIA, WORKSHOPS AND VISITING PROFESSORSHIPS

Osler Institute: Neurology Board Review Course, Neurogenetics Lecture and organization of oral exam portion of the course, 1991.

American Academy of Neurology, Boston. Course Chairman for seminar: The Neurofibromatoses: from phenotypes to the genes, 1991.

American College of Physicians, MKSAP 2-day course, Section on review of neurological disorders. Los Angeles, 1992.

American Academy of Neurology, Course Chairman for seminar: The Phakomatoses: from phenotypes to the genes, San Diego, 1992.

Universita degli studi 'G. d'Annunzio', Visiting professor: Chieti, Italy, 1992.

Valley Presbyterian Hospital, Internal Medicine Update: a two day intensive course. Section on review of neurological disorders, Los Angeles, 1992.

University of Chicago, FLEX examination review, section on neurological diseases, Pasadena California, 1993.

Osler Institute: Neurology Review Course, San Diego, 1993.

Cedars-Sinai Medical Center, First Annual Symposium on the Diagnosis and Treatment of Parkinson's disease. Program Chair, Los Angeles, 1993.

Osler Institute: Pediatric Neurology, Pediatric Board Review Course, Los Angeles, 1993.

Cedars-Sinai Medical Center, Second Annual Symposium on the Diagnosis and Treatment of Parkinson's disease. Program Chair, Los Angeles, 1994.

Osler Institute Teaching Symposium, San Francisco, 1994.

Osler Institute Neurology Review Course, Seattle, 1996

Harvard Medical School, Visiting Professor Longwood Neurology Program. Boston, 1996

IVth International Meeting of the von Recklinghausen Society. Satellite symposium. Molecular genetic tools for the analysis of human genetic disease. Hamburg, Germany, 1996.

SYMPOSIA, WORKSHOPS AND VISITING PROFESSORSHIPS (continued)

IVth International Meeting of the von Recklinghausen Society. Scientific session chair: Neurofibromatosis 2. Hamburg, Germany, 1996.

American Academy of Neurology, Course Director 'Molecular Genetic Testing for Neurological Diseases'. Boston, 1997

NIH/NNFF/House Ear Institute Workshop on NF2: Present & Future. Rockville, MD, 1997.

Osler Institute Neurology Board Review Course, Los Angeles, 1998.

American Academy of Neurology, Course Director, "Molecular Genetic Testing for Neurological Diseases." Minneapolis, MN, 1998.

Osler Institute Neurology Board Review Course, San Francisco, 1999.

National Ataxia Foundation. "Clinical and molecular aspects of the inherited ataxias." Organizer and Course Director, Los Angeles, 1999.

American Academy of Neurology, Course Director, "Molecular Genetic Testing for Neurological Diseases." Minneapolis, MN, 1999.

Neuroscience Program, University of Southern California, Los Angeles, 1999.
Visiting Professor.

Movement Disorder Society, Ataxia Satellite, Organizing committee, Seattle, 1999.

American Academy of Neurology, Course Director, "Molecular Genetic Testing for Neurological Diseases." San Diego, California, 2000.

Harvard Medical School. Visiting Professor in Neurology, Beth Israel Deaconess Medical Center, Boston, 2003.

Chair, Symposium: 'From Cage to Bedside', Meeting of the American Academy of Neurology, San Francisco, 2004.

Co-chair, Future of Neurosciences conference: Stem Cells and Neurological Disease. Meeting of the American Academy of Neurology, San Diego, 2006.

RESEARCH PAPERS - PEER REVIEWED

1. **Pulst SM:** Infrared-thermography in the diagnosis of sympathetic lesions (in German). ***Akt Neurol*** 8:43-47, (1981)
2. **Pulst SM,** Haller P: Thermographic assessment of impaired sympathetic function in peripheral nerve injuries.
   J Neurol 226:35-42 (1981)
3. **Pulst SM:** The value of infrared thermography in the assessment of monotopic lesions of the peripheral nervous system. (in German)
   Arztez Nature Phys Med Rehab 22: 147-153 (1981)
4. Wolpers MC, **Pulst SM:** Carotid thrombosis following blunt trauma to the neck (in German).
   Akt Neurol 9:83:-86 (1982)
5. Dietl HW, **Pulst SM,** Engelhardt P, Mehrain P: Paraneoplastic brainstem encephalitis with acute dystonia and central hypoventilation.
   J Neurol 227:229-238 (1982)
6. **Pulst SM,** Walshe, TM, Romero JA: Carbon monoxide poisoning with features of Gilles de la Tourette's Syndrome.
   Arch Neurol 40:(7) 443-444 (1983)
7. **Pulst SM,** Lombroso CT: External ophthalmoplegia, alpha and spindle coma in imipramine overdose: case report and review of the literature.
   Ann Neurol 14:587-590 (1983)
8. **Pulst SM:** Neurologic complications in the acquired immunodeficiency syndrome (AIDS): A clinical, computer tomographic and neuropathologic case study and review of the literature (in German).
   Nervenarzt 55:407-412 (1984)
9. **Pulst SM,** Levin VA, Deen DF: In vitro pharmacokinetics and cytotoxicity of dibromodulcitol using the 9L rat brain tumor cell line.
   Pharmac Res 3:302-306 (1986)
10. **Pulst SM,** Gusman D, Rothman BS, Mayeri E: Co-existence of egg-laying hormone and alpha-bag cell peptide in bag cell neurons of Aplysia indicates that they are a peptidergic multitransmitter system.
    Neurosci Let 70:40-45 (1986)
11. **Pulst SM,** Rothman BS, Mayeri E: Presence of immunoreactive alpha-bag cell peptide (1-8) in bag cell neurons of Aplysia suggests novel carboxypedtidase processing of neuropeptides.
    Neuropeptides 10:249-259 (1987)
12. **Pulst SM**, Gusman D, Mayeri E: Immunostaining for peptides of the egg-laying hormone/bag cell peptide precursor protein in the head ganglia of Aplysia.
    Neuroscience 27:363-371 (1988).

RESEARCH PAPERS - PEER REVIEWED (continued)

13. Brown RO, **Pulst SM:** Mayeri E: Neuroendocrine bag cells of Aplysia are activated by bag cell peptide-containing neurons in the pleura ganglion.
J Neurophysiol 61:1142-52 (1989).
14. Korenberg JR, **Pulst SM:** Neve RL, West R: The Alzheimer amyloid precursor protein maps to human chromosome 21 bands q21.105 - q21.05.
Genomics 5:124-127 (1989)
15. **Pulst SM:** Korenberg JR, Greenwald J, Carbone M: A new restriction fragment length polymorphism at the D21S13 locus.
Hum Genet 84:580 (1990)
16. **Pulst SM:** Graham J, Barker D, Fain P, Pribyl T, Korenberg JR: The achondroplasia gene is not linked to the locus for neurofibromatosis 1 on chromosome 17.
Hum Genet 85:12-14 (1990)
17. Korenberg JR, Kawashima H, **Pulst SM:** Ikeuchi T, Ogasawa N, Yamamoto K, Schonberg SA, West R, Allen L, Magenis E, Ikawa K, Taniguchi Epstein CJ: Molecular definition of a region of chromosome 21 that causes features of the Down syndrome phenotype.
Am J Hum Genet 47: 236-246 (1990)
18. **Pulst SM,** Korenberg JR: A panel of aneuploid cell lines for the physical mapping or the proximal long arm of human chromosome 21.
Am J Med Genet (Suppl 7): 137-140 (1990)
19. Korenberg JR, Magenis A, **Pulst SM,** Kawashima H, Ikeuchi T, Yamamoto K, Ogasawa N, Schonberg SA, West R, Kojis T, Epstein CJ: Down syndrome and normal chromosomes.
Am J Med Genet (Suppl 7): 91-97 (1990)
20. **Pulst SM**, Ren M, Greenwald J, Korenberg JR: A new HaeIII polymorphism for the D21S13 locus.
Hum Genet 85:571 (1990)
21. **Pulst SM,** Deen DF: Potentiation of BCNU-induced cytotoxicity and sister chromatid exchanges by Dibromodulcitol in vitro.
Anticancer Res 10:1647-1650 (1990)
22. Korenberg JR, Kalousek DK, Anneren G, **Pulst SM**, Hall JG, Epstein CJ, Cox DR: Deletion of chromosome 21 and normal intelligence: molecular definition of the lesion.
Hum Genet 87:112-118 (1991)
23. **Pulst SM,** Fain P, Cohn V, Nee LE, Polinsky RJ, Korenberg JR: Exclusion of linkage to the pericentromeric region of chromosome 21 in pedigree with Familial Alzheimer disease.
Hum Genet 87:159-161 (1991)
24. Shohat M, Herman V, Melmed S, Neufeld N, Schreck R, **Pulst SM**: Rimoin DL, Korenberg JR: Deletion of 20p11.23 - pter with normal growth hormone neurosecretory disorder, but normal growth hormone releasing hormone genes.
Am J Med Genet 39:56-63 (1991)

RESEARCH PAPERS - PEER REVIEWED (continued)

25. **Pulst SM,** Pribyl T, Barker D, Ren M, Yaari H, Riccardi VM, Korenberg JR: Molecular analysis of a patient with neurofibromatosis 1 and achondroplasia.
Am J Med Genet 40:84-87 (1991)

26. Falik-Borenstein TC, Pribyl T, Van Dyke DL, **Pulst SM:** Chu ML, Kraus J, Korenberg JR: Stable ring chromosome 21: Molecular and clinical definition of the lesion.
Am J Med Genet 42: 22-28 (1991)

27. **Pulst SM,** Riccardi *VM,* Fain P, Barker D, Korenberg JR: Familial spinal neurofibromatosis: clinical and DNA linkage studies.
Neurology 41:923-927 (1991)

28. **Pulst SM,** Yang-Feng T, Korenberg JR: Relative order and location of DNA sequences on chromosome 21 linked to Familial Alzheimer Disease.
Am J Med Genet 41:454-459 (1991)

29. Sieb JP, **Pulst SM,** Buch A: Familial CNS tumors.
J Neurol 239:343-344 (1992)

30. Huynh D, Lin C, **Pulst SM:** Expression of neurofibromin, the Neurofibromatosis 1 gene product: studies in human neuroblastoma and rat CNS.
Neurosci Let 143:233-236 (1992)

31. Kamino K, Orr HT, Payami H, Wijsman EM, Alonso ME, **Pulst SM** L, O'Dahl S, Nemens E, Korenberg JR, White JA, Sadovnick AD, Ball MJ, Warren A, Sharma V, Kukull W, Larson E, Heston LL, Martin GM, Bird TD, Schellenberg GD: Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region.
Am J Hum Genet 51: 998-1014 (1992)

32. Mautner VF, Tatagiba M, Hazim W, Quester R, Samii M, **Pulst SM:** Neurofibromatosis 2 in the pediatric age group.
Neurosurgery 33:92-96 (1993)

33. Nechiporuk A, Fain P, Kort E, Nee LE, Frommelt E, Polinsky RJ, Korenberg JR, **Pulst SM,** Linkage of familial Alzheimer disease to chromosome 14 in two large early onset pedigrees: effects of marker allele frequencies on lod scores.
Am J Med Gen 48:63-66 (1993)

34. Rouleau G, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, **Pulst SM,** Lenoir G, Bjillsma E, Fashold R, Dumanski J, DeJong P, Parry D, Eldrige R, Aurias A, Delattre O, Thomas G: Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2.
Nature 363:515-521 (1993)

35. **Pulst SM,** Nechiporuk A, Starkman S: Anticipation in spinocerebellar ataxia type 2.
Nature Genetics 5:8-10 (1993)

RESEARCH PAPERS - PEER REVIEWED (continued)

36. Sainz J, Rasmussen J, Nechiporuk A, Vissing H, Cheng X, Korenberg JR, **Pulst SM:** Dinucleotide repeat polymorphism at the D22S351 locus.
Hum Molecular Genetics. 2:1749 (1993)

37. Mautner VF, **Pulst SM:** Non-classified types of neurofibromatosis
Akt Neurol 20:123-128 (1993)

38. **Pulst SM,** Fain P, Rouleau GA, Sieb JP: Familial meningioma is not allelic to NF2.
Neurology 43:2096-2098 (1993)

39. Sainz J, Nechiporuk A, Kim UJ, Simon MI, **Pulst SM**: CA-repeat polymorphism at the D22S430 locus adjacent to NF2.
Hum Mol Genet 2: (12) 2203 (1993)

40. Sainz J, Baser M, Ragge N, Nelson R, **Pulst SM**: Loss of alleles on chromosome 22 in vestibular schwannomas: use of microsatellite markers.
Arch Otolaryng Head Neck Surg 119:1285-1288 (1993)

41. Huynh D, Nechiporuk T, **Pulst SM:** Differential Expression and Tissue Distribution of Type I and Type II Neurofibromin During Mouse Fetal Development.
Develop Biol 161:538-551 (1994)

42. Huynh D, Nechiporuk T, **Pulst SM**: Alternative transcripts in the mouse neurofibromatosis type 2 (NF2) gene are conserved and code for schwannomins with distinct C-terminal domains.
Hum Mol Genet 3:(7)1075-1079 (1994)

43. Sainz J, Huynh D, Figueroa K, Ragge NK, Baser ME, **Pulst SM**: Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas.
Hum Mol Genet 3:885-891(1994)

44. Merel P, Hoang-Xuan K, Sanson M, Bijlsma E, Rouleau G, Laurent-Puig P, **Pulst SM**, Baser M, Lenoir G, Sterkers JM, Philippon J, Resche F, Mautner V, Fischer G, Hulsebos T, Aurjas A, Delattre O, Thomas G: Screening for germ-line mutations in the NF2 gene.
Genes Chromosomes and Cancer. 12:117-127 (1995)

45. Kluwe L, **Pulst SM,** Koppen J, Mautner VF: A 163 bp deletion in the Neurofibromatosis 2 gene.
Hum. Genet. 95 (4) 443-446 (1995)

46. Mautner V, Tatagiba M, Lindenau M, Funsterer C, **Pulst SM,** Kluwe L, Zanella F: Spinal tumors in neurofibromatosis type 2.
Am J Roentgen 165: 951-955 (1995)

47. Gispert S, Lunkes A, Santos N, Orozco G, Ha-Hao D, Ratzlaff T, Aguiar J, Torrens I, Brice A, Schalling M, Lindblad K, Heredero L, Weissenbach J, Fukui K, Cancel G, Stevanin G, Vernant JC, Durr A, Lepage-Lezin A, Belal S, Ben Hamida MB, **Pulst SM,** Rouleau G, Kucherlapati R, Montgomery K, Lepaslier D, Auburger G: Localization of the candidate gene D-amino acid oxidase outside the refined 1 centiMorgan region of Spinocerebellar Ataxia 2 (SCA2).
Am J Hum Genet 57: 975-977 (1995)

RESEARCH PAPERS - PEER REVIEWED (continued)

48. Sainz J, Figueroa K, Mautner V, Baser M, **Pulst SM:** High frequency of nonsense mutations in the NF2 gene caused by C to T transitions in five CGA codons.
Hum Mol Genet 4: 137-139 (1995)

49. Ragge KN, Baser ME, Klein J, Nechiporuk A, Sainz J, **Pulst SM,** Riccardi VM: Ocular abnormalities in neurofibromatosis 2.
Am J Ophthal 120: 634-641 (1995)

50. Kim UJ, Shizuya H, Sainz J, Garnes J, **Pulst SM,** DeJong P, Simon MI: Construction and utility of a human chromosome 22-specific Fosmid library.
Genetic Analysis: Biomolecular Engineering 12:81-84 (1995)

51. Sainz J, Figueroa P, **Pulst SM:** Identification of three NF2 gene mutations in vestibular schwannomas.
Hum Genet 97:121-123 (1996)

52. Nechiporuk T, Nechiporuk A, Guan X, Frederick R, Figueroa K, Chumakov I, Korenberg J, de Jong P, **Pulst SM**: Identification of three new microsatellite markers in the spinocerebellar ataxia type 2 (SCA2) region and 1.2 Mb physical map.
Hum Genet 97:462-467 (1996)

53. Mautner, V, Lindenau M, Hazim W, Tatagiba M, Haase W, Samii M, Wais R, **Pulst SM:** The neuroimaging and ocular spectrum of neurofibromatosis 2.
Neurosurgery 38:5, 880-886 (1996)

54. Nechiporuk A, Lopez-Cendes I, Nechiporuk T, Starkman S, Anderman E, Rouleau GA, Weissenbach JS, Kort E, **Pulst SM**: Genetic mapping of the spinocerebellar ataxia type 2 gene on human chromosome 12.
Neurology 46: 1731-1734 (1996)

55. Huynh D, **Pulst SM:** NF antisense oligodeoxynucleotides induce reversible inhibition of schwannomin synthesis and cell adhesion in STS26T and T98G cells.
Oncogene 13: 73-84 (1996)

56. Scoles D, Baser M, **Pulst SM**: A missense mutation in the neurofibromatosis 2 gene occurs in patients with mild and severe phenotypes.
Neurology 47:544-546 (1996)

57. Baser ME, Ragge NK, Riccardi VM, Ganz B, Janus T, **Pulst SM**: Phenotypic variability in monozygotic twins with neurofibromatosis 2.
Am J Med Genet 64: 563-567 (1996).

58. Huynh D, Ho V, **Pulst SM:** Expression of presenilin 1 in the mouse nervous system.
Neuroreport 7: 2423-2428 (1996)

59. Huynh D, Tran M, Nechiporuk T, **Pulst SM:** Expression of Neurofibromatosis 2 transcript and gene product during mouse fetal development.
Cell Growth Differentiation 7:1551-1561 (1996)

RESEARCH PAPERS - PEER REVIEWED (continued)

60. Baser M, Mautner VF, Ragge N, Nechiporuk A, Riccardi VM, Klein J, Sainz J, **Pulst SM**: Presymptomatic diagnosis in neurofibromatosis 2 using linked genetic markers, neuroimaging, and ocular examinations.
Neurology 47:1269-1277 (1996)

61. **Pulst SM**, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN, Lopes-Cendes I, Perlman S, Starkman S, Orozco-Diaz G, Lunkes A, de Jong P, Rouleau GA, Auburger G, Korenberg JR, Figueroa C, Sahba S: Identification of the SCA2 gene: Moderate expansion of a normally biallelic trinucleotide repeat.
Nature Genetics 40: 269-276 (1996)

62. Geschwind DH, Perlman S, Figueroa CP, Treiman LJ, **Pulst SM**: The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 (SCA2) trinucleotide repeat in patients with autosomal dominant cerebellar ataxia.
Am J Hum Genet 60: 842-850 (1997)

63. Huynh DP, Mautner V, Baser, ME, Stavrou D, **Pulst SM**: Immunohistochemical detection of schwannomin and neurofibromin in vestibular schwannomas, ependymomas and meningiomas.
J Neuropathol Exp Neurology 56: 382-390 (1997)

64. Riess O, Laccone FA, Gispert S, Schols L, Zuhlke C, Viera-Saecker AMM, Herit S, Wessel K, Epplen JT, Weber BHF, Kreuz F, Chalrok-Zadek S, Meindl A, Lunkes A, Aguiar J, Macek M Jr, Krebsova A, Macek M sen, Buerk K, **Pulst SM**, Auburger G: SCA2 trinucleotide expansion in German SCA patients.
Neurogenetics 1: 59-64 (1997)

65. Sutton D, **Pulst SM:** Atypical Parkinsonism in a family of Portuguese ancestry: Absence of CAG repeat expansion in the MJD1 gene.
Neurology 48: 1285-1290 (1997).

66. Huynh D, **Pulst SM**: Expression of presenilin 1 and 2 in normal brain and Alzheimer disease brains.
J Neuropathol Exp Neurol 56: 9 1009-1017 (1997).

67. Nechiporuk T, Nechiporuk A, Sahba SD, Figueroa KP, Shibata H, Chen XN, Korenberg JR, de Jong P, Pulst SM: A High Resolution PAC and BAC Map of the SCA2 Region.
Genomics 44: 321-329 (1997).

68. Adams C, Starkman S, Pulst SM: Phenotype of SCA2 in a large kindred from Southern Italy.
Neurology 49: 1163-1166 (1997).

69. Geschwind DH, Perlman S, Figueroa KP, Karrim J, Baloh RW, **Pulst SM**: Spinocerebellar ataxia type 6: Frequency of the mutation and genotype-phenotype correlations.
Neurology 49: 1247-1251 (1997).

70. Schols L, Gispert S, Vorgerd M, Menezes Viera-Saecker AM, Blanke P, Auburger G, Amoirides G, Meves S, Epplen J, Przuntek H, Pulst SM, Riess O: Spinocerebellar ataxia type 2: Genotype and phenotype in German kindreds.
Arch Neurol 54: 1073-1080 (1997).

RESEARCH PAPERS - PEER REVIEWED (continued)

71. Grotta J: Lubeluzole treatment of acute ischemic stroke. For the US and Canadian Lubeluzole Ischemic Stroke Study Group. **Pulst SM**: (Contributor) ***Stroke*** 28: 2338-2346 (1997).
72. Gouw LG, Castaneda MA, McKenna CK, Digre KB, **Pulst SM**, Perlman S, Lee MS, Gomez C, Fischbeck K, Gagnon D, Storey E, Bird T, Jeri FR, Ptacek LJ: Analysis of the dynamic mutation in the SCA7 gene shows marked parental effects on CAG repeat transmission. ***Hum Mol Genet*** 7:525-532 (1998).
73. Sahba S, Nechiporuk A, Figueroa K, Nechiporuk T, **Pulst SM**: Genomic structure of the human gene for spinocerebellar ataxia type 2 (SCA2) on chromosome 12q24.1. ***Genomics*** 47:359-364, (1998).
74. Scoles DR, Huynh D, Coulsell E, Robinson G, Tamanoi F, **Pulst SM:** The neurofibromatosis 2 tumor suppressor schwannomin interacts with βII-spectrin (fodrin). ***Nature Genetics*** 18:1-6 (1998).
75. Nechiporuk T, Huynh D, Figueroa K, Sahba S, Nechiporuk A, Pulst SM: The mouse SCA gene: cDNA sequence, alternative splicing, and protein expression. ***Hum Mol Genet*** 7:1301-1309 (1998).
76. Mautner VF, Schroeder S, Pulst SM, Ostertag H, Kluwe L: Neurofibromatosis versus schwannomatosis. ***Fortschr Neurol Psychiat*** 66: 271-277 (1998).
77. Buttner N, Geschwind D, Jen JC, Perlman S, **Pulst SM,** Baloh RW: Oculomotor phenotypes in the SCA syndromes. ***Arch Neurol*** 55:1353-1357 (1998).
78. Grewal R, Tayag E, Figueroa KP, Zu L, Durazo A, Nunez C, **Pulst SM**: Clinical and genetic analysis of a distinct autosomal dominant spinocerebellar ataxia. ***Neurology*** 51: 1423-1426 (1998).
79. Huynh DH, Marc R. Del Bigio, Sahba S, Diane H. Ho, **Pulst SM:** Expression of ataxin 2 in brains from normal individuals and patients with Alzheimer disease and spinocerebellar ataxia 2 (SCA2). ***Ann Neurol*** 45: 232-241 (1999).
80. Zu L, Figueroa KP, Grewal R, **Pulst SM:** Mapping of a new autosomal dominant spinocerebellar ataxia (SCA10) to chromosome 22. ***Am J Hum Genet*** 64:594-599 (1999).
81. Kuo, AA, **Pulst SM,** Eliashiv SD, Adams CR: Electrical inexcitability of nerves and muscles in severe infantile spinal muscular atrophy. ***J Neurol Neurosurg Psych*** 67:122 (1999).
82. Simon D, **Pulst SM**, Sutton JP, Beal MF, Johns DR: Familial parkinsonism due to a mutation in a mitochondrial DNA encoded complex I subunit. ***Neurology*** 53:1787-93 (1999).

RESEARCH PAPERS - PEER REVIEWED (continued)

83. Shibata H, Huynh DP, **Pulst SM**: A Novel Protein with RNA Binding Motifs interacts with Ataxin-2.
Hum Mol Genet 9: 1303-1313 (2000).

84. Hayes S, Turecki G, Brisebois K, Lopes-Cendes I, Gaspar C, Riess O, Ranum LPW, **Pulst SM**, Rouleau GA: CAG repeat length in *RAI1* is associated with age at onset variability in spinocerebellar ataxia type 2 (SCA2).
Hum Mol Genet 9:1753-1758 (2000).

85. Scoles, D, Guttman D, Chen M, Morrison H, Huynh D, **Pulst SM:** Interaction of the Neurofibromatosis 2 (NF2) tumor suppressor schwannomin with HRS.
Hum Mol Genet 22: 1303-13 (2000).

86. Huynh DP, Figueroa K, Hoang N, **Pulst SM**: Nuclear localization or inclusion body formation are not necessary for SCA2 pathogenesis in mouse or human.
Nature Genetics 26 :44-50 (2000).

87. Huynh DP, Scoles DR, Ho TH, Del Bigio MR, **Pulst SM**: Parkin is associated with actin filaments in neuronal and nonneural cells.
Ann Neurol 48:737-44 (2000).

88. Matsuura T, Yamagata The, Burgess DL, Rasmussen A, Grewal RP, Watase K, Khajavi M, McCall A, Davis CF, Zu L, Acharyu M, **Pulst SM**, Alonso E, Noebels JL, Nelson DL, Zoghbi HY, Ashizawa T: Large expansion of ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10.
Nature Genetics 26:191-194 (2000).

89. Kiehl TR, Shibata H, **Pulst SM**: The ortholog of human ataxin-2 is essential for early embryonic patterning in *C. elegans*.
J Mol Neurosci 15: 231-241 (2000).

90. Bruder CE, Hirvela C, Tapia-Paez I, Fransson I, Segraves R, Hamilton G, Zhang XX, Evans DG, Wallace AJ, Baser ME, Zucman-Rossi J, Hergersberg M, Boltshauser E, Papi L, Rouleau GA, Poptodorov G, Jordanova A, Rask-Andersen H, Kluwe L, Mautner V, Sainio M, Hung G, Mathiesen T, Moller C, **Pulst SM**, Harder H, Heiberg A, Honda M, Niimura M, Sahlen S, Blennow E, Albertson DG, Pinkel D, Dumanski JP: High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH.
Hum Mol Genet 10: 271-282 (2001).

91. So YT, Zu L, Barraza C, Figueroa KP, **Pulst SM**: Rippling muscle disease. Evidence for phenotypic and genetic heterogeneity.
Muscle Nerve 11: 503-507 (2001).

92. Gutmann DH, Haipek CA, Burke SP, Sun CX, Scoles DR, **Pulst SM**: The NF2 interactor, hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), associates with merlin in the 'open' conformation and suppresses cell growth and motility.
Hum Mol Genet 10: 825-834 (2001).

93. Costa RM, Yang T, Huynh DP, **Pulst SM**, Viskochil DH, Silva AJ and Brannan CI: Learning deficits but normal development and tumor predisposition in mice lacking exon 23a of the Neurofibromatosis type 1 gene.
Nature Genetics 27: 399-411 (2001).

RESEARCH PAPERS - PEER REVIEWED (continued)

94. Konakova M, Huynh DP, Yong W, Pulst SM: Cellular distribution of torsinA and torsinB in normal human brain.
Arch Neurol 58:921-7 (2001).

95. Kiehl TR, Shibata H, Vo T, Huynh DP, **Pulst SM**: Identification and expression of a mouse ortholog of A2BP1.
Mamm Genome 12:595-601 (2001).

96. Figueroa KP, Chan P, Schols L, Tanner C, Riess O, Perlman SL, Geschwind DH, **Pulst SM**: Association of moderate polyglutamine tract expansions in the slow calcium-activated potassium channel type 3 with ataxia.
Arch Neurol 58: 1755-1777 (2001).

97. Sobrido MJ, Cholfin JA, Perlman S, **Pulst SM**, Geschwind DH: SCA8 repeat expansions in ataxia: a controversial association.
Neurology 57: 1310-1312 (2001).

98. Huynh DP, Dy M, Nguyen D, Kiehl TR, **Pulst SM**: Differential expression and tissue distribution of parkin isoforms during mouse development.
Brain Res Dev Brain Res 130: 173-181 (2001).

99. Cholfin JA, Sobrido MJ, Perlman S, **Pulst SM**, Geschwind DH: The SCA12 mutation as a rare cause of spinocerebellar ataxia.
Arch Neurol 58: 1833-1835 (2001).

100. Konakova M, Huynh DP, **Pulst SM**: Immunocytochemical characterization of torsin proteins in the mouse brain.
Brain Res 922: 1-8 (2001).

101. Scoles DR, Chen M, **Pulst SM**: Effects of NF2 missense mutations on schwannomin interactions.
Biochem Biophys Res Commun 290:366-374 (2002).

102. Grewal RP, Achari M, Tohru Matsuura, MD, Alberto Durazo, MD, Emilio Tayag, MD, Lan Zu, **Pulst SM,** Ashizawa: The Clinical Features and ATTCT Repeat Expansion in Spinocerebellar Ataxia Type 10.
Arch Neurol 59:1285-1290 (2002).

103. Adams CR, Figueroa KP, Zu L, Anderson TL, Graves MC, Garcia CA, **Pulst SM**: Bethlem Myopathy in a Black Creole Pedigree.
J Clin Neuromuscular Dis 4: 7-10 (2002).

104. Bhidayasiri R, **Pulst SM**: Segmental unilateral lentiginosis in generalized neurofibromatosis type 1.
Arch Neurol 59:1331-2 (2002).

105. Sun, CX, Haipek, C., Scoles, DR, **Pulst SM**, Giovannini M, Komada M, Gutmann DH: Functional analysis of the relationship between the neurofibromatosis 2 (NF2) tumor suppressor and its binding partner, hepatocyte growth factor-regulated tyrosine kinase substrate (HRS/HGS).
Hum Mol Genet 11: 3167-3178 (2002).

RESEARCH PAPERS - PEER REVIEWED- continued

106. Scoles DR, Nguyen VD, Qin Y, Sun CX, David H. Gutmann, and **Pulst SM:** Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling.
Hum Mol Genet 11: 3179-3189 (2002).

107. Huynh DG, Vakharia H, Nguyen D, **Pulst SM**: Expansion of the polyglutamine repeat in ataxin-2 causes its subcellular redistribution and apoptotic cell death.
Hum Mol Genet 12:1485-96 (2003).

108. Huynh DP, Scoles DR, Nguyen D, **Pulst SM**: The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI.
Hum Mol Genet 12(20):2587-97 (2003).

109. Figueroa KP, **Pulst SM**: Identification and expression of the gene for human ataxin-2 related protein on chromosome 16.
Exp Neurol 184:669-678 (2003).

110. Oh MK, Scoles DR, Gutmann DH, **Pulst SM**: Genetic heterogeneity of stably transfected cell lines revealed by expression profiling with oligonucleotide microarrays.
J Cell Biochem 90: 1068-1078 (2003).

111. Matsuura T, Fang P, Lin X, Tsuji K, Rasmussen A, **Pulst SM**, Zoghbi HY, Nelson DL, Roa BB, Tetsuo Ashizawa: Somatic and Germline Instability of the ATTCT Repeat in Spinocerebellar Ataxia Type 10.
Am J Hum Genet 74: 1216-1224 (2004)

112. Fee D, So Y, Barraza C, Figueroa KP, Pulst SM: Phenotypic Variability Associated with Arginine26Glutamine Mutation in Caveolin3.
Muscle & Nerve 30: 375-378 (2004).

113. Glass AS, Huynh DP, Franck T, Woitalla D, Muller T, **Pulst SM**, Berg D, Kruger R, Riess O. Screening for mutations in synaptotagmin XI in Parkinson's disease.
J Neural Transm Suppl: 68:21-8 (2004).

114. Konakova M, **Pulst SM**: Dystonia-associated forms of torsinA are deficient in ATPase activity.
J Mol Neurosci 25: 105-118 (2005).

115. **Pulst SM**, Santos N, Wang D, Yang HY, Huynh D, Velazquez L, Figueroa KP: Spinocerebellar ataxia type 2: polyQ repeat variation in the CACNA1a channel modifies age of onset.
Brain 128: 2297-303 (2005)

116. Scoles DR, Qin Y, Nguyen V, Gutmann DH, **Pulst SM**: HRS inhibits EGF receptor signaling in the RT4 rat schwannoma cell line.
Biochem Biophys Res Commun 335:385-392. (2005)

117. Waters MF, Fee D, Figueroa KP, Nolte D, Muller U, Advincula J, Coon H, Evidente VG, **Pulst SM**. An autosomal dominant ataxia maps to 19q13: Allelic heterogeneity of SCA13 or novel locus?
Neurology 65: 1111-1113. (2005).

RESEARCH PAPERS - PEER REVIEWED- continued

117. Bhidayasiri R, Perlman S, **Pulst SM**, Geschwind DH: Late-onset Friedreich's ataxia: phenotypic analysis, magnetic resonance imaging findings, and review of the literature. ***Arch Neurol*** 62: 1865-1869 (2005).

118. Kiehl TR, Nechiporuk A, Figueroa KP, Keating MT, Huynh DP, **Pulst SM**: Generation and characterization of *Sca2* (ataxin-2) knockout mice. ***Biochem Biophys Res Commun*** 339: 17-24 (2006).

119. Scoles DR, **Pulst SM**: Nf2 and p110 interaction: a role for translational control in brain tumors. ***Hum Mol Genet*** (epub 2-25-06) 15: 1059-1070 (2006).

120. Waters MF, Minassian NA, Stevanin G, Figueroa KP, Bannister JPA, Nolte D, Mock AF, Evidente VG, Fee D, Müller U, Dürr A, Brice A, Papazian DM, **Pulst SM**: Mutations in the voltage-gated potassium channel KCNC3 cause degenerative and developmental CNS phenotypes. ***Nature Genetics*** (epub 2-26-06) 4: 447-451 (2006).

RESEARCH PAPERS - PEER REVIEWED- in press

121. Simon D, Figueroa KP, Velazquez L, Santos N, **Pulst SM**: Mitochondrial complex I gene variant associated with early age of onset in SCA2. ***Arch Neurol***

RESEARCH PAPERS - PEER REVIEWED- Submitted

122. Huynh DP, Nguyen D, Pulst-Korenberg JB, Brice A, Pulst SM: Parkin is an E3 ubiquitin ligase for normal and mutant ataxin-2 and prevents ataxin-2-induced cell death. ***Exp Neurol***

123. Willeumier K, Pulst SM, Schweizer FE: Proteasome Inhibition Triggers Activity-Dependent Increase in the Size of the Recycling Vesicle Pool in Hippocampal Neurons ***J. Neurosci***

124. Huynh DP, Nguyen D, Vu L, **Pulst SM**: Parkin-mediated ubiquitylation and degradation of synaptotagmin I and suppression of synaptotagmin I-induced cell death. ***J Biol Chem***

RESEARCH PAPERS - NON PEER REVIEWED

1. Ashizawa T, Clark HB, Koeppen AH, Pandolfo M, Paulson H, **Pulst SM**, Richter A, Robitaille Y, Subramony SH, Wilson R. The Hereditary Ataxias: A symposium of the Society for Experimental Neuropathology under the auspices of the American Neurological Association. **The Cerebellum** 143-158 (2002).

BOOKS

1. Molecular genetic testing in Neurology, **SM Pulst** (ed.), AAN Press, Minneapolis 1996; 2nd edition 1997, 3rd edition 1998, 4th edition 1999, 5th edition 2000.
2. Neurogenetics. **SM Pulst** (editor). 458 pages, Oxford University Press, New York, 2000.
3. Genetics of Movement Disorders. **SM Pulst** (editor). 561 pages, Academic Press, San Diego, (2003).
4. Genetics in Neurology. **SM Pulst** (ed.), AAN Press, Minneapolis 2005.
5. The Ataxias. **Pulst SM** & Brice A (eds). Churchill Livingston, (in press).

BOOK CHAPTERS

1. **Pulst SM**: Sympathetic lesions (in German). In: Lesions and Diseases of Peripheral Nerves. Wieck HH, Schrader A, Daun H, Kielgelye B, (eds) pp 27-33. Perimed Fachbuch-Verlagsgesellschaft mbh, Erlangen, 1984.
2. **Pulst SM**: Prenatal diagnosis of the neurofibromatoses. In "Clinics in Perinatology", pp 829-844 W.B. Saunders, Philadelphia, 1990.
3. **Pulst SM**: The neurofibromatoses. In 'Decision making in pediatric ophthalmology', Cibis, Tongue, Stass-Isern eds., ABC Decker-Moby-Year Book, Inc., St. Louis, 1993.
4. **Pulst SM**: Methods and strategies in molecular genetics. AAN Press, T Bird (ed.), 1994.
5. **Pulst SM**: Basic Molecular Genetics for Neurologists; AAN Press, # 345 page 345-17, T. Bird (ed.), 1995.
6. **Pulst SM:** Molecular genetics of brain tumors. In: 'Emory & Rimoin's Principle and Practice of Medical Genetics', DL Rimoin, JM Connor, RE Pyeritz, AEH Emery (eds.), Churchill Livingston, 1996.
7. **Pulst SM**: Basic Molecular Genetics for Neurologists; in 'Genetics in Neurology', T. Bird (ed.), AAN Press, # 244 page 21-38, 1996.
8. **Pulst SM**: Introduction to Molecular Genetic Testing. In ' Molecular genetic testing in Neurology', SM Pulst (ed.), AAN Press, page 21-38, 1996.
9. **Pulst SM**: Basic Molecular Genetics for Neurologists; in 'Genetics in Neurology', T. Bird (ed.), AAN Press, # 244 page 21-38, 1996.
10. **Pulst SM**: Introduction to Molecular Genetic Testing. In ' Molecular genetic testing in Neurology', SM Pulst (ed.), AAN Press, page 21-38, 1996.
11. **Pulst SM**: Basic Molecular Genetics for Neurologists; in 'Genetics in Neurology', T. Bird (ed.), AAN Press, #244 page 21-38, 1997.
12. **Pulst SM**: Introduction to Molecular Genetic Testing. In ' Molecular genetic testing in Neurology', SM Pulst (ed.), AAN Press, pages 21-38, 1997.

BOOK CHAPTERS (continued)

13. **Pulst SM:** Spinocerebellar ataxia type 2. In 'Genetic Instabilities and Hereditary Neurological Diseases.' Wells, R.D. and S.T. Warren (eds.), Academic Press, San Diego, 1998.
14. Mautner VF, **Pulst SM**: Phakomatosen. In "Neurogenetik", Riess O, Schoels L (eds), Springer Verlag, Berlin-Heidelberg, 1998.
15. **Pulst SM:** Spinocerebellar ataxia type 2. In 'Unstable triplet repeat diseases.' Rubinsztein DC and Hayden MR (eds.), Bios Scientific Publishers, Oxford, Washington DC (1998).
16. **Pulst SM**: SCA2. In 'Geneclinics', T. Bird, R. Pagon (eds.) http://www.geneclinics.org/profiles/sca2, 1999.
17. **Pulst SM**: Introduction to Medical Genetics. In "Neurogenetics", Pulst SM (ed), Oxford University Press, New York, 2000.
18. **Pulst SM**: Molecular Genetic Tools. In "Neurogenetics", Pulst SM (ed), Oxford University Press, New York, 2000.
19. **Pulst SM,** Reifenberger G: Primary Tumors of the Nervous System. In "Neurogenetics", Pulst SM (ed), Oxford University Press, New York, 2000.
20. **Pulst SM,** Gutmann D: Phakomatoses. In "Neurogenetics", Pulst SM (ed), Oxford University Press, New York, 2000.
21. **Pulst SM,** Perlman SL: Hereditary Ataxias. In "Neurogenetics", Pulst SM (ed), Oxford University Press, New York, 2000.
22. **Pulst SM**: Spinocerebellar Ataxia type 10. In "Neurological Ataxia", Klockgether T, (ed), Marcel Dekker, New York, 2000.
23. **Pulst SM**: Neurogenetics. In "Neurology Update". AAN Press, Minneapolis, MN, 2000.
24. **Pulst SM**: SCA2. In 'Geneclinics', T. Bird, R. Pagon (eds.) http://www.geneclinics.org/profiles/sca2, 2001.
25. **Pulst SM**: Spinocerebellar ataxia type 2. In 'Hereditary ataxias. Manto & Pandolfo M (eds.), Cambridge University Press Washington DC (in press).
26. **Pulst SM**: Spinocerebellar Ataxia type 10. In "Hereditary ataxias. "Manto & Pandolfo M (eds.), Cambridge University Press Washington DC (in press).
27. Scoles DR, **Pulst SM:** Molecular genetics of brain tumors. In: "Emory & Rimoin's Principle and Practice of Medical Genetics", DL Rimoin, JM Connor, RE Pyeritz, AEH Emery (eds.), Churchill Livingston (2002).
28. **Pulst SM**: Basic Terminology and Methods in Genetics. In "Molecular Genetic Testing." AAN Press, Minneapolis (2002).
29. **Pulst SM**: Introduction to Medical Genetics and Methods of DNA testing. In: "Genetics of Movement disorders", Pulst SM (ed), pp. 2-18, Academic Press, San Diego, (2003).

BOOK CHAPTERS (continued)

30. **Pulst SM**: Inherited Ataxias: An introduction. In: "Genetics of Movement disorders", Pulst SM (ed), pp. 19-34, Academic Press, San Diego, (2003).
31. **Pulst SM**: Spinocerebellar ataxia type 2. In: "Genetics of Movement disorders", Pulst SM (ed), pp. 45-56, Academic Press, San Diego, (2003).
32. Vakharia H, Oh MK, **Pulst SM**: Spinocerebellar ataxia type 11. In: "Genetics of Movement disorders", Pulst SM (ed), pp. 117-120, Academic Press, San Diego, (2003).
33. Nance M, Bird TD, **Pulst SM**: Ethical Issues in Genetic Testing for Movement disorders. In: "Genetics of Movement disorders", Pulst SM (ed), pp. 541-550, Academic Press, San Diego, (2003).
34. **Pulst SM**: The phakomatoses. In "Genetics in Neurology. SM Pulst (ed.), AAN Press, Minneapolis 2005.
35. **Pulst SM:** Spinocerebellar ataxia type 2. In 'Genetic Instabilities and Hereditary Neurological Diseases.' Wells, R.D. and Ashizawa T. (eds.), Academic Press, San Diego (in press).
36. Scoles DR, **Pulst SM:** Molecular genetics of brain tumors. In: "Emory & Rimoin's Principle and Practice of Medical Genetics", DL Rimoin, JM Connor, RE Pyeritz, AEH Emery (eds.), Churchill Livingston (in press).
37. **Pulst SM,** Paulson H: Cell and animal models of polyglutamine ataxia. In "Hereditary Ataxias and Spastic Paraplegias, A. Brice, SM Pulst (eds.), Elsevier in press.
38. **Pulst SM**: The phakomatoses. In "Genetics in Neurology. SM Pulst (ed.), AAN Press, Minneapolis 2006.

EDITORIALS

1. **Pulst SM**, Filla A: Ataxias on the march from Quebec to Tunisia.
   Neurology 54:1400-1. (2000)
2. **Pulst SM:** Ethics of DNA testing.
   Muscle Nerve 23: 1503-1507 (2000)
3. **Pulst SM:** Genomes, neuroscience, and neurology.
   Arch Neurol 58: 1755-1757 (2001).

LETTERS TO THE EDITOR

1. **Pulst SM**: Survival of patients with gliomas under therapy with anticonvulsants.
   Nervenarzt 53:612 (1982)
2. **Pulst SM:** Diagnosis of von-Recklinghausen-Neurofibromatosis
   Dtsch Med Wochenschr 114: 647-8 (1989)
3. **Pulst SM**, Riccardi V, Mautner VF: Familial schwannomatosis.
   Neurology 48: 787-788 (1997).
4. **Pulst SM**: Letter to Surgical Neurology: "Harada H, et al: Neurofibromatosis type 2 with multiple primary brain tumors in monozygotic twins.
   Surg. Neurol. 53: 95 (2000).

REVIEWS

1. **Pulst SM:** Use of infra-red thermography for the diagnosis of peripheral nerve lesions (in German)
   Physikalische Medizin und Rehabilitation, Georg Thieme Verlag, (1982).
2. Mautner V, Laute S, Schneider E, **Pulst SM**: Neurofibromatoses: current clinical and molecular aspects from the neurologic viewpoint (in German)
   Nervenarzt 62: 340-348 (1991).
3. **Pulst SM:** The diagnosis of Neurofibromatosis.
   Dtsch Med Wschr 116:394 (1991).
4. **Pulst SM**: Genetic linkage analysis and neurologic disease.
   Arch Neurol 56: 667-672 (1999).
5. **Pulst SM:** Ataxias expanding again. Neurology Network Commentary 3:239-241 (1999).
6. Lim DJ, Rubenstein AE, Evans DG, Jacks T, Seizinger BG, Baser ME, Beebe D, Brackmann DE, Chiocca EA, Fehon RG, Giovannini M, Glazer R, Gusella JF, Gutmann DH, Korf B, Lieberman F, Martuza R, McClatchey AI, Parry DM, **Pulst SM**, Ramesh V, Ramsey WJ, Ratner N, Rutkowski JL, Ruttledge M, Weinstein DE: Advances in Neurofibromatosis 2 (NF2): A Workshop Report. *J Neurogenet* 14: 63-106 (2000).
7. Adams C, **Pulst SM**: Global Misregulation of Gene Expression in Facioscapulohumeral Muscular Dystrophy. Lancet Neurology Network Commentary (2000).
8. **Pulst SM**: Neurogenetics. Encyclopedia of the Neurological Sciences (2003).
9. **Pulst SM**: Hypomelanosis of Ito. Encyclopedia of the Neurological Sciences (2003).
10. **Pulst SM**: Incontinentia pigmenti. Encyclopedia of the Neurological Sciences (2003).
11. **Pulst SM**: Neurogenetics: single gene disorders. J Neurol Neurosurg Psych (2003).
12. **Pulst** SM: Spinocerebellar Ataxia Type 2 (updated January 2006) in: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle. 1997-2006. Available at http://www.genetests.org.
13. Bhidayasiri R, **Pulst SM**: Dystonia (DYT) genetic loci.
    ***Eur J Paediatr Neurol* (2005)**

ABSTRACTS

1. Lorenz R, **Pulst SM**, Engelhardt P: Side-effects of BCNU. Proceedings of the Pula Neurological Meeting (1982)
2. **Pulst SM**, Deen DF: Dibromodulcitol potentiates the cytotoxicity and induction of sister chromatid exchanges by BCNU in vitro. J Neurol 23 (Suppl):148, (1985)
3. Lombroso CT, **Pulst SM**: Imipramine induced spindle-alpha coma with ophthalmoplegia. EEG Cl Neurol 56(4):p28. (1985)
4. **Pulst SM** , Levin VA, Deen DF: Cytotoxicity of Dibromodulcitol (D3D) in vitro. Pharmacokinetic observations using a bioassay. Rad Res (Suppl) 9: Gfl6, (1985)
5. **Pulst SM**, Gusman D, Rothman BS, Mayeri E: Co-localization of alpha bag cell peptide and egg laying hormone in bag cell neurons of *Aplysia californica*. Soc Neurosci Abstr 11:481,(1985)
6. **Pulst SM**, Gusman D, Rothman BS, Mayeri E: Possible differential] processing of the ELH/BCP precursor in Aplysia. 30th International Congress of Physiological Sciences, (1986)
7. **Pulst SM**, Mayeri E: Comparison of different paper assays for antibody crossreactivity. J Histochem Cytochem 34:1360, (1986)
8. **Pulst SM**, Rothman BS, Mayeri E: The presence of immunoreactive alpha-bag cell peptide (1-8) in bag cell neurons of Aplysia California suggests the existence of novel carboxypedtidase processing. Soc. Neuroscience (1986)
9. Korenberg JR, West R, **Pulst SM**: The Alzheimer protein precursor gene maps to chromosome 21 sub-bands q21.15-q21.2. Am Acad Neurology (1988)
10. Korenberg JR, **Pulst SM,** West R, Schonberg SA, Epstein CJ: Down syndrome with normal chromosomes: superoxide dismutase and the amyloid precursor protein are not duplicated. Am Fed Clin Res. (1988)
11. Korenberg JR, **Pulst SM**, Kawashima H, Ikeuchi T, Yamamoto 1, Ogasawa N, Schonberg SA, West R, Kojis T, Epstein CJ: Familial Down syndrome with normal karyotype: molecular definition of the region. Am J Hum Genet (Suppl) 43: A 777, (1988)
12. **Pulst SM**, Korenberg JR, Pribyl T, Stewart GS, Tanzi RE, Van Brockhaven C, West R, Kojis T, Epstein CJ: Familial Alzheimer-linked DNA sequences cluster in a probable hot spot of recombination. Am J Hum Genet (Suppl) 43:A 621, (1988)
13. **Pulst SM**, Korenberg JR: Alzheimer disease and Down syndrome: Molecular studies on chromosome 21. Neurology (Suppl) 39:249 (1989)
14. **Pulst SM**, Korenberg JR, West R, Kojis T: Physical mapping of DNA sequences linked to familial Alzheimer disease. Neurology (Suppl) 39: 249 (1989)
15. **Pulst SM**, Pribyl TM, Riccardi V, Kojis T, Korenberg JR: Molecular genetic analysis of a patient with neurofibromatosis 1 and achondroplasia Neurology (Suppl) 39: 249 (1989)

ABSTRACTS (continued)

16. Shohat M, Herman V, Schreck R, **Pulst SM**, Neufeld N, Melmed S, Korenberg JR: Growth hormone neurosecretory disorder due to deletion of 20p1.23-pter, but with normal growth hormone releasing factor genes (GHRF). 10th International Meeting on Human Gene Mapping (1989)

17. Korenberg JR, **Pulst SM**, Kawashima H, Epstein CJ, Allen L, Magenis E: A molecular map of the Down syndrome phenotype. 10th International Meeting on Human Gene Mapping (1989)
18. Korenberg JR, Barker D, Fain P, Graham J, Pribyl T, **Pulst SM**: Achondroplasia is not tightly linked to the locus for neurofibromatosis 1. 10th International Meeting on Human Gene Mapping. (1989)
19. **Pulst SM**, Falik-Borenstein Z, Pribyl T, Kojis T, Korenberg JR: Physical order of DNA probes linked to Familial Alzheimer disease. 10th International Meeting on Human Gene Mapping. (1989)
20. Korenberg JR, **Pulst SM**, Falik-Borenstein TC, Kojis T, Pribyl T: Toward a physical map of chromosome 21. Cold Spring Harbor, April (1989)
21. **Pulst SM**, Falik-Borenstein, Z., Pribyl, T., Kojis, T., Korenberg, JR.: Chromosome 21 physical map: order of DNA probes linked to Familial Alzheimer Disease. International Symposium on Trisomy 21, Rome Italy (1989)
22. Korenberg JR, **Pulst SM**, Kawashima H, Epstein CJ, Aller L, Magenis E.: Down syndrome: toward a molecular definition of the phenotype. International Symposium on Trisomy 21, Rome, Italy, (1989)
23. Falik-Borenstein TC, Pribyl T, Van Dyke DL, **Pulst SM,** Chu ML, Kraus J, Kojis T, Korenberg JR: A stable ring chromosome 21: Molecular and clinical definition of the lesion. March of Dimes, Boston, (1989)
24. **Pulst SM**, Riccardi V, Ren M, Barker DF, Fain P, Korenberg JR: Spinal neurofibromatosis is linked to the neurofibromatosis 1 region on Chromosome 17. Am J Hum Genet 45: A 615 (1989).
25. Pribyl T, Korenberg JR, Barker D, Fain P, Ren M, Graham J, **Pulst SM**: The gene for achondroplasia is not tightly linked to the locus for neurofibromatosis 1. Am J Hum Genet 45: A 614 (1989)
26. Ren M, Riccardi V, Fain P, Barker D, Korenberg JR, **Pulst SM**: Linkage of Familial Spinal Neurofibromatosis to the Neurofibromatosis 1 locus on chromosome 17. Neurology 40 (Suppl 1): 388 (1990)
27. Korenberg JR, **Pulst SM**: Mapping of DNA sequences near the FAD gene on chromosome 21. Neurology 40 (Suppl I): 388 (1990)
28. **Pulst SM**, Cohn V, Polinsky RJ, Greenwald JL, Nee LE, Korenberg JR: Genetic linkage analysis of Familial Alzheimer disease with a new polymorphism in the D21S13 locus. Neurology 40 (Suppl 1): 387 (1990)

ABSTRACTS (continued)

29. Korenberg JR, Falik-Borenstein TC, Muenke M, Mennuti MC, **Pulst SM**: Partial Monosomies of Chromosome 21 and Mental Retardation: Molecular definition of the region. Am J Hum Genet 47 (Suppl): (1990)
30. Camiso P, **Pulst SM**, Patterson D, Korenberg JR: Mapping of DNA sequences near the FAD gene on chromosome 21. Am J Hum Genet: 47 (Suppl): (1990)
31. **Pulst SM**, Fain P, Cohn V, Nee LE, Polinsky RJ, Korenberg JR: Exclusion of linkage to D21S13 in the Canadian pedigree with Familial Alzheimer Disease. Am J Hum Genet 47 (Suppl): (1990)
32. Sears TA, Riccardi V, Fain P, Barker D, Korenberg JR, **Pulst SM**: Non-allelic heterogeneity of Familial Spinal Neurofibromatosis. Am J Hum Genet 47 (Suppl): (1990)

33. Korenberg JR, Falik-Borenstein, Muenke M, Mennuti MC, **Pulst SM**: Molecular map of mental retardation on chromosome 21. Neurology 41 (Suppl): 215 (1991)
34. Stewart GD, Martin CA, Casetti AV, Buraczynska M, **Pulst SM**, Korenberg JR: Identification of sequences and walking in YACs. Proceedings of the 8th International Congress of Human Genetics. Washington. Oct. 6-11, 49:441 (1991)
35. **Pulst SM**, Korenberg JR: Identification of large human chromosome DNA fragments cloned in Yeast Artificial chromosomes near the ALS locus on chromosome 21. First International Conference on Neuromuscular Diseases, Los Angeles. (1992)
36. **Pulst SM**, Fain P, Sieb J: Linkage analysis of familial meningioma. Meeting of the NNFF international consortium on gene cloning and gene function of NF1 and NF2. Salt Lake City, (1992)
37. Seaman J, Fain P, Polinsky R, Nee L, Frommelt P, Korenberg JR, **Pulst SM**: Genetic linkage analysis of the German pedigree with Familial Alzheimer disease with new polymorphisms in the D21S13 locus. Neurology 42 (Suppl 3): 350 (1992)
38. NG P, **Pulst SM**: Not so benign thunderclap headache. Neurology 42 (Suppl 3): 422P (1992)
39. Korenberg JR, **Pulst SM**: Molecular map of Mental Retardation on Human Chromosome 21. Neurology 42 (Suppl 3): 592S (1992)
40. Mautner VF, Tatagiba M, Laute S, Guthoff R, Samii M, **Pulst SM**: Clinical and genetic analysis of Neurofibromatosis (NF) type 2. Neurology 42 (Suppl 3): 1109P (1992)
41. Huynh D, **Pulst SM**: Expression of the Neurofibromatosis 1 Gene Product: Studies in Human Neuroblastoma Cells and Rat Brain. Neurology 42 (Suppl 3): 167S (1992)
42. **Pulst SM**, Rouleau G, Fain P, Sieb JP: Familial meningioma is not allelic to Neurofibromatosis 2. Am J Hum Genet 51 (Suppl 4): 413 (1992)
43. Ragge NK, Baser ME, Falk RE, Nelson RA, Shannon R, Riccardi VM, **Pulst SM**: Presymptomatic diagnosis of NF2: ocular expression. Am J Hum Genet 51 (Suppl 4): 113 (1992)

ABSTRACTS (continued)

44. Huynh D, Nechiporuk T, **Pulst SM**: Expression of type 1 and type 2 Neurofibromin in mouse Fetal Development. NNFF International Consortium on Gene Cloning and Gene Function. Ann Arbor, Michigan, April (1993)
45. Baser ME, Sainz J, Ragge NK, Nechiporuk A, Riccardi VM, Klein J, Nelson RA, **Pulst SM**: Molecular and clinical studies in Neurofibromatosis type 2. NNFF International Consortium on Gene Cloning and Gene Function Ann Arbor, Michigan, (1993)
46. Baser ME, **Pulst SM**, Ragge NK, Sainz J, Riccardi VM, Shannon RV, Klein J, Nelson RA: Neurofibromatosis Type 2. A Clinical-Molecular Approach. Am Acad Otolaryng, AAO-HNS Bulletin 1993; 12:30. (1993)
47. Korenberg JR, Chen X-N, Mitchell S, Patterson D, **Pulst SM,** Su Z-G, Kim UJ, Birren B, Simon M: The chromosome 21 Mega-YAC library: size order, and chimerism. The 4th international Workshop on Chromosome 21. Paris, France. (1993)
48. **Pulst SM**, Baser ME, Mautner V, Sainz J, Nechiporuk A, Klein J, Nelson RA, Ragge NK: Presymptomatic diagnosis in NF2: Use of novel microsatellite markers, neuroimaging and ocular examinations. Am J Hum Genet 53:3 (Suppl): 488 (1993)
49. Korenberg JR, Chin X-N, Mitchell T, Sun Z-G, Patterson D, **Pulst SM**: An integrated cytogenetic molecular and genetic map of chromosome 21. Am J Hum Genet 53 :3 (Suppl) 1314 (1993)

50. Nechiporuk A, Starkman S, **Pulst SM**: Spinocerebellar ataxia type 2 (SCA): flanking markers on chromosome 12 and evidence for anticipation. Am J Hum Genet 53:3 (Suppl): 1049 (1993)
51. Sainz J, Figueroa C, Baser ME, **Pulst SM**: Mutations in the neurofibromatosis 2 gene in 31 vestibular schwannomas. Am J Hum Genet 53:3 (Suppl): A488 (1993)
52. Kluwe L, Mautner V, Sainz J, Baser M, **Pulst SM**: Presymptomatic diagnosis in NF2 families and loss of heterozygosity analysis in schwannomas with microsatellite markers. Third annual neurofibromatosis meeting, Hamburg, Germany (1993)
53. Ragge NK, Baser M, Klein J, Falk RE, **Pulst SM**, Nechiporuk A, Murphree AL, Riccardi VM: A survey of ocular abnormalities in neurofibromatosis type 2. College of Ophthalmology Annual Congress, Guernsey, (1994)
54. Nechiporuk A, Frederick T, Lopes-Cendes I, Rouleau GA, Weissenbach JS, Kort E, **Pulst SM**: Genetic map of the spinocerebellar ataxia type 2 (SCA2) region on chromosome 12. Am J Hum Genet 53:3:A200 (1994)
55. Huynh D, Nechiporuk T, Lin C, Mautner V, **Pulst SM**: The NF2 gene product: Expression in human 8th nerve, NF2 tumors, and fetal mouse tissues. Am J Hum Genet 53:3:A125 (1994)
56. **Pulst SM**, Nechiporuk A, Nechiporuk T, Lopes-Cendes I, Rouleau G, Kort E, DeJong P, Weissenbach J, Chumakov I: Genetic and physical map of the spinocerebellar ataxia 2 (SCA2) region on human chromosome 12. Neurology 45 (Suppl 4) 931S (1995).
57. Huynh D, **Pulst SM**: Inhibition of NGF mediated differentiation of PC12 cells by treatment with NF1 antisense oligonucleotides. Neurology 45 (Suppl 4) 423S (1995).

ABSTRACTS (continued)

58. Klein J, Baser M, Ragge N, Riccardi V, **Pulst SM**: Presymptomatic diagnosis of neurofibromatosis type 2. 2nd Annual Meeting of the American College of Medical Genetics (1995)
59. Scoles D, Sainz J, Huynh DP, **Pulst SM**: Mutational analysis of the neurofibromatosis type 2 gene. Meeting of the International Consortium on NF1 and NF2 gene cloning and function. Philadelphia, (1995)
60. Huynh DP, Tran M, Nechiporuk T, **Pulst SM**: Expression of Neurofibromatosis 2 transcript and gene product during mouse fetal development. Meeting of the International Consortium on NF1 and NF2 gene cloning and function. Philadelphia (1995)
61. Huynh DP, **Pulst SM**: Antisense oligonucleotides complementary to the neurofibromatosis type 1 gene inhibit NGF mediated differentiation of PC12 cells. Meeting of the International Consortium on NF1 and NF2 gene cloning and function. Philadelphia (1995)
62. Baser M, Ragge N, Riccardi B, Ganz B, Janus T, **Pulst SM**: Neurofibromatosis 2 in monozygotic twins. American Society of Human Genetics 45th Annual Meeting. Minneapolis, 1995
63. **Pulst SM**, Nechiporuk A, Chumakov I, Guan X, DeJong P, Nechiporuk T: YAC and PAC map of the spinocerebellar ataxia type 2 region on chromosome 12. American Society of Human Genetics 45th Annual Meeting. Minneapolis, 1995
64. Sutton J, **Pulst SM:** Atypical Parkinsonism in a family of Portuguese Ancestry. Fourth National Parkinsons's disease research. San Diego (1995)
65. Sutton JP, **Pulst SM**: Familial Parkinsonism in a Kindred of Portuguese Descent: Absence of known markers for Machado-Joseph Disease. Platform presentation, AAN Annual Meeting, San Francisco, 1996, Neurology (in press)

66. **Pulst SM,** Huynh D: NF2 Gene Mutations and Schwannomin Immunoreactivity in Sporadic Schwannomas, Meningiomas, and Ependymomas. Platform presentation, AAN Annual Meeting, San Francisco, 1996, Neurology (in press)
67. Nechiporuk A, Guan K, DeJong P, Chumakov I, Nechiporuk T, Sahba SD, Figueroa P, **Pulst SM**: Toward the Identification of the Spinocerebellar Ataxia Type 2 (SCA2) Gene on Chromosome 12q24.1. AAN Annual Meeting, San Francisco, 1996, Neurology (in press)
68. Huynh D, Vinter V, Ho V, **Pulst SM**: Detection of Presenilin (PS-1) and PS-2) in Mouse Brain and in normal and Alzheimer's Disease human brains. Am J Hum Genet 59:4 (Suppl) A141 (1996)
69. Nechiporuk A, Nechiporuk T, Figueroa K, Sahba S. Korenberg, JR, De Jong P, Perlman S, Gispert S, Lunkes A, Rouleau G, Lopes-Cendes-I, Auburger G, **Pulst SM:** Spinocerebellar ataxia type 2 (SCA2) is caused by expansion of a CAG trinucleotide repeat which is stable in the normal population.
Am J Hum Genet 59:4 (Suppl) A48 (1996)
70. Nechiporuk T, Figueroa KP, Nechiporuk A, Huynh DG, Geschwind D, Pearlman **Pulst SM:** The spinocerebellar ataxia type 2 (SCA2) gene: cDNA sequence, expression and frequency of the repeat expansion.
Am J Hum Genet 59:4 (Suppl) A99 (1996).

ABSTRACTS (continued)

71. Scoles DR, Huynh DP, Coulsell ER, Robinson NGG, Tamanoi F, **Pulst SM:** The neurofibromatosis 2 gene product schwannomin interacts with β II-spectrin. Am J Hum Genet 59:4 (Suppl) A5 (1996)
72. Huynh D, Vinter V. Ho V, **Pulst SM:** Detection of Presenilin (PS-1 and PS-2) in mouse brain and in normal and Alzheimer's Disease Human brains. Society of Neuroscience annual meeting, Washington, DC. (1996)
73. Scoles D, Huynh D, Coulsell E, Robinson NG, Tamanoi F, **Pulst SM:** Identification and characterization of interaction between the NF2 gene product schwannomin and βII-spectrin. 6th International Congress on Cell Biology, San Francisco, (1996)
74. Shibata H, **Pulst SM**: The SCA2 gene: genomic structure, related genes, and phenotypes. Unstable triplets, microsatellites, and human disease. Santa Fe, NM, 1997.
75. Geschwind D, Perlman S, **Pulst SM**: Frequency and clinical phenotype of mutations in the gene for spinocerebellar ataxia type 2 (SCA2). Neurology (Suppl 2) 48: A 176 (1997).
76. Lopes-Cendes I, Andermann E, Nechiporuk A, Teive H, Jain S, **Pulst SM**, Rouleau GA: Frequency and molecular characteristics of the spinocerebellar ataxia type 2 mutation. Neurology (Suppl 2) 48: A 177 (1997).
77. Pulst SM, Nechiporuk The, Nechiporuk A: Characterization of the spinocerebellar ataxia type 2 (SCA2) gene. Neurology (Suppl 2) 48: A 209 (1997).
78. Marcos PA, Scoles DR, Huynh DP, Cousell ER, **Pulst SM**: Characterization of fodrin interaction with the NF2 tumor suppressor gene product schwannomin (merlin) and varying strengths of protein binding that correlate with NF2 patient phenotype. Neurology (Suppl 2) 48: A 393 (1997).
79. Nechiporuk T, Nechiporuk A, Sahba S, Figueroa KP, Chen X, Shibata, H., Korenberg, JR, **Pulst SM:** A High Resolution PAC and BAC Map of the spinocerebellar ataxia type 2 (SCA2) region. 4th International workshop on human chromosome 12. Nice, France, 1997.
80. **Pulst SM**, Nechiporuk A, Nechiporuk T, Sahba SD, Geschwind DH, Perlman S, Figueroa KP: Characterization of the spinocerebellar ataxia type 2 (SCA2) gene. 4th International workshop on human chromosome 12. Nice, France, 1997.
81. Geschwind DH, Perlman S, Schols L, Riess O, Auburger G, Figueroa KP, Pulst SM: Spinocerebellar ataxia type 2 (SCA2): Frequency of the mutation in sporadic ataxia patients, dominant ataxia kindreds, and genotype/phenotype correlations. International ataxia meeting, Montreal, Canada, 1997.
82. **Pulst, SM**, Nechiporuk, A, Nechiporuk T, Sahba SD, Geschwind, DH, Perlman S, Figueroa, KP: Characterization of the spinocerebellar ataxia type 2 (SCA2) gene. International ataxia meeting, Montreal, Canada, 1997.
83. **Pulst SM**, Nechiporuk A, Sahba SD, Geschwind DH, Perlman S, Figueroa KP, Nechiporuk T: The spinocerebellar ataxia type 2 (SCA2) gene. International meeting on Machado-Joseph disease. Curitiba, Brazil, 1997.

ABSTRACTS (continued)

84. **Pulst SM**: Shibata H, Del Bigio M, Huynh DP: Spinocerebellar ataxia type 2 (SCA2): binding proteins, subcellular localization and post-translational Processing", Minneapolis, 1998.

85. Scoles D & **Pulst SM**: The neurofibromatosis type 2 protein, binding proteins and phenotypes in patients. National Neurofibromatosis Foundation Clinical Care Conference, Los Angeles, 1998
86. Figueroa KP, Zu L, So Y, Adams S, **Pulst SM**: Locus heterogeneity of Rippling Muscle disease (RMD) ASHG annual meeting, Denver, Colorado 1998.
87. Huynh D, Scoles D, Faudoa R, Li X, **Pulst SM**: Study of NF2 gene function in primary vestibular schwannoma cultures. ASHG annual meeting, Denver, Colorado 1998.
88. Huynh DP, Hiroki D, Ho T, Sabha S, Del Bigio M, **Pulst SM**: Spinocerebellar Ataxia type 2 (SCA2) Subcellular localization and protein interaction. American Society Cell Biology annual meeting. San Francisco, CA 1998
89. Shibata H, Huynh D, V T, Pulst SM: The SCA2 gene product ataxia 2 interacts with a novel RNA-Binding protein predominantly expressed in the CNS. ASHG annual meeting, Denver, Colorado. 1998
90. Scoles DP, Huynh D, Ho E, Kimchi EY, Pulst SM: The Neurofibromatosis 2 (NF2) interacting protein SBP3 has impaired interaction with mutant schwannomin and is not expressed in vestibular schwannomas. American Society Cell Biology, San Francisco, CA 1998.
91. Huynh DP, Ho T, Sabha S, Del Bigio M, **Pulst SM:** Spinocerebellar Ataxia Type 2: (SCA2): Subcellular localization and protein interaction. Annual meeting of Society of Neuroscience. Los Angeles, CA 1998.
92. Figueroa K, Zu L, So Y, Adams C, **Pulst SM**: Evidence for a second locus for Rippling Muscle Disease (RMD) Annual American Academy of Neurology Meeting, Canada 1999. Page A122 Neurology vol. 52 (suppl 2)
93. Huynh DP, H Koeppen AH, Shibata H, Ho Trang, Sahba Soodabeh, Hoan Nam, Figueroa K, Del Bigio M, **Pulst SM**: Absence of Intranuclear Aggregates an Animal Model. Annual American Academy of Neurology Meeting, Canada 1999. Page A7 Neurology vol. 52 (suppl 2)
94. Shibata, H, Huynh D, Vo T, **Pulst SM**: The SCA Gene Product. Ataxin-2 interact with a Novel protein A2BP, a Member of a RNA Binding Gene Family. Annual American Academy of Neurology Meeting, Canada 1999. Page A259 Neurology vol. 52 (suppl 2)
95. Zu L, Figueroa K, Grewal R, **Pulst SM**: Mapping of a New Autosomal Dominant Spinocerebellar Ataxia. (ScA10) to a 15 cM Region on Chromosome 22. Annual American Academy of Neurology Meeting, Canada 1999. Page A260 Neurology vol. 52 (suppl 2)
96. Scoles D, Huynh D, Ho D, **Pulst SM:** The Neurofibromatosis 2 (NF2) Interacting Protein SBP3 is not expressed in vestibular schwannomas. Annual American Academy of Neurology Meeting, Canada 1999.
Neurology 52 (suppl 2): A474 (1999).

ABSTRACTS (continued)

97. Petzinger G, Figueroa KP, Jakowec W, Fahn S, **Pulst SM**: Double Mutants for Huntington and Spinocerebellar Ataxia Type 2 (SCA2) in a Large Pedigree Segregating Both Mutations. Annual American Academy of Neurology Meeting, San Diego 2000.
Neurology 54 (suppl 3): A192.
98. Geschwind D, Sobrido M, Lavian P, **Pulst SM**, Perlman S: SCA8 Repeat Length in Patients with inherited or Sporadic Ataxia. Annual American Academy of Neurology Meeting, San Diego 2000.
Neurology 54: A357 (2000).

99. Zu L, Figueroa K, Barraza C, Grewal R, **Pulst SM**: Fine Mapping of the SCA10 Region on Chromosome 22. Annual American Academy of Neurology Meeting, San Diego 2000. Neurology 54: A357 (2000).
100. Scoles D, Gutmann DH, Chen M, Morrison H, Huynh D, **Pulst SM**: Neurofibromatosis 2 (NF2) Tumor Suppressor Schwannomin Interaction with HRS Regulates STAT Signaling and Schwann Cell Proliferation. Annual meeting of the American Academy of Neurology, San Diego 2000. Neurology 54: A7 (2000).
101. Huynh D, Scoles D, Del Bigio M, **Pulst SM**: Parkin is Associated with Actin Filaments of Neuronal and Nonneural Cells. Annual American Academy of Neurology Meeting, San Diego 2000.Neurology 54: A264 (2000).
102. Konakova M, Huynh D, **Pulst SM:** Functional Analysis of Ataxin-2: In Vivo Self-Aggregation and Subcellular Localization. Annual meeting of the American Academy of Neurology, San Diego 2000.
Neurology 54: A464 (2000).
103. Kiehl RT, Nechiporuk A, Shibata H, **Pulst SM**: Knockout Models for Ataxin-2 and Ataxin-2-Binding-Protein: Gene Function, Developmental Genetics, and Clinical Relevance. Annual Meting of the American Academy of Neurology, San Diego 2000.
Neurology 54: A464 (2000).
104. Matsuura T, Burgess DL, Yamagata T, Rasmussen A, Grewal RP, Watase K, Tsuji K, Khajavi M, McCall A, Davis CF, Yescas P, Zu L, **Pulst SM**, Alonso E, Noebels JL, Nelson DL, Zoghbi HY, Ashizawa T: Large Expansion of ATTCT Pentanucleotide Repeat in Spinocerebellar Ataxia Type 10 (SCA10). American Society of Human Genetics Annual Meeting, Philadelphia 2000. Am J Hum Genet, 67 Number 4 (suppl 2): 55 (2000).
105. Kiehl RT, Nechiporuk A, Luthringer DJ, **Pulst SM**: Developmental role for ataxin-2 and the fox-1 homolog A2BP1. American Society of Human Genetics Annual Meeting, Philadelphia 2000. Am J Hum Genet, 67 Number 4 (suppl 2): 172 (2000).
106. Ashizawa T, Matsuura T, Rasmussen A, Grewal RP, Zu L, **Pulst SM,** Pandolfo M, Sasaki H, Volpini V, Yamagata T, Watase K, Burgess DL, Inoue K, Yescas P, Nagamitsu S, Momor MY, Tashiro K, Zoghbi HY, Alonso E, Nelson DL: Founder effect of the spinocerebellar ataxia type 10 mutation in the Mexican Population. American Society of Human Genetics Annual Meeting, Philadelphia 2000.
Am J Hum Genet, 67 Number 4 (suppl 2): 373 (2000).

ABSTRACTS (continued)

107. Huynh D, **Pulst SM**: Animal models in neurodegenerative diseases. Vietnamese Society for Clinical biochemistry. Hanoi, Vietnam. October 2000.
108. Huynh Dp, Nguyen D, Dy M, **Pulst SM**: Parkin interacts with Synaptic vesicle associated proteins. Annual Meeting of the Society for Neuroscience, San Diego California (2001).
109. Konakova M. and **Pulst SM:** TorsinA and torsinB expression in the adult and embryonic rodent central nervous system. 53rd Annual Meeting of the American Academy of Neurology. Philadelphia, USA) (2001).
110. **Pulst SM**, Santos N, Velazquez L and Figueroa KP (2001) Length of CAG repeat in the SCA1 gene, but not APOE status, modifies age of onset in spinocerebellar ataxia type 2 (SCA2). ASHG annual meeting, San Diego, California (2001)
111. Figueroa K, Santos, N, Velazquez, L, **Pulst SM:** Normal variation in SCA 1 and SCA6 CAG repeats modifies age of onset in spinocerebellar ataxia type 2 (SCA2). Platform presentation, AAN Annual Meeting, Denver Colorado, Neurology vol. 58 Number 7 Supplement 3: A16 (2002).

112. Scoles, D.R. Nguyen V, Lam S, **Pulst SM:** The NF2 tumor suppressor schwannomin interacts with p110, a component of the eukaryotic initiation factor 3 (eIF3). Platform presentation, 54th American Academy of Neurology Annual Meeting, Denver, Colorado, Neurology vol. 58 Number 7 Supplement 3: A11 (2002).

113. Huynh D, Tao, H, **Pulst SM:** Expansion of the polyQ tract in ataxin 2 disrupts Golgi localization. Platform presentation, 54th American Academy of Neurology Annual Meeting, Denver, Colorado, Neurology vol. 58 Number 7 Supplement 3: A12 (2002).

114. Huynh DP, Nguyen D, Dy M, **Pulst SM**: Parkin interacts with synaptic vesicle associated proteins. Platform presentation, Annual American Academy of Neurology Meeting Denver, Colorado. Neurology vol. 58 Number 7 Supplement 3: A410 (2002).

115. Scoles, D.R., Nguyen, V., Gutmann, D.H., **Pulst SM**: The NF2 tumor suppressor interacting protein HRS regulates EGF receptor trafficking in schwannoma cells. Neurology (Suppl. 3) (2003)

116. Scoles, D.R., Gutmann, D.H. **Pulst SM:** The neurofibromatosis 2 (NF2) tumor suppressor schwannomin interacting protein HRS regulates EGF receptor signaling and trafficking in schwannooma cells. Am. J. Hum. Genet. Vol 73(5) (Suppl). Pg 197 (2004)

117. Qin, Y., **Pulst S**, and Scoles, D.R. The NF2 tumor suppressor schwannomin interacts with the eukaryotic initiation factor 3 (eIF3) subunit p110. Am. J. Hum Genet. 73 (5) (Suppl). Pg 198 (2004).

118. Scoles, D.R., Gutmann, D.H., and **Pulst, S.M.** HRS regulates EGF receptor signaling and trafficking in schwannoma cells. Mol. Biol. Cell (Suppl): (2004).

119. Pulst SM, Santos N, Wang D, Yang H. Velazquez, LL. Figueroa P. **Pulst, SM**: Genetic modifiers of disease onset in spinocerebellar ataxia type 2 (SCA2). 56th Annual Meeting AAN San Francisco (2004).

120. Pulst-Korenberg, JB, Huynh D, Nguyen D, Pulst SM: SCA2 and parkin interaction: parkin reduces cell death in a cell culture model of polyglutamine-induced cell death. Neurology 62 (Suppl 5) A1

121. Fee D, Licht B, Figueroa K, Harper, K, Hyson L, **Pulst SM**: Purebred Canine Epilepsy: A Link between Inbreed Rodents and Humans (56th Annual Meeting AAN) San Francisco (2004).

122. Evidente, G Fee D, Advincula J, Nolte D, Mueller U, **Pulst SM:** Novel Autosomal Dominant Cerebellar Ataxia Syndrome in a Filipino Kindred.(56th Annual Meeting AAN) San Francisco, CA (2004).

123. Figueroa KP, Kiehl T-R, Xuan X, **Pulst SM**: Knock-out of the Ataxin-2 (SCA2) Gene Causes Hyperphagia and Marked Obesity. (56th Annual Meeting AAN) San Francisco, CA (2004).

124. Konakova M, **Pulst SM**: Dystonia-associated mutations in torsin A result in reduced ATPase activity. (56th annual Meeting AAN) San Francisco, CA (2004)

125. Waters MF, Fee N, Figueroa KP, Coon H, Evidente V, **Pulst SM**: An autosomal dominant ataxia maps to 19q13: allelic heterogeneity of SCA13 or novel locus? (130 annual Meeting ANA) San Diego, CA (2005) Presentation (Works in Progress).